Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz ACN Newswire

Bank Mandiri Enhances Digital Resiliency for Financial Trading in Indonesia through Advanced Time Sync Solutions with NEC and Adtran Oscilloquartz

TOKYO, Dec 12, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701), a leader in the integration of IT and network technologies, today announced that Indonesia-based Bank Mandiri has selected NEC’s Network Transformation Service to implement Adtran’s innovative Oscilloquartz time synchronization technology in its Jakarta data centers, elevating the bank’s digital infrastructure. With this new secure timing solution, Bank Mandiri is reinforcing its abilities to comply with stringent global banking regulations, which enables effective auditing for fraud prevention and enhances operational efficiency.As one of the largest banks in Indonesia, Bank Mandiri aims to be the preferred financial partner for its customers by seamlessly integrating its financial products and services into their daily lives through the delivery of simple, fast digital banking solutions. While Bank Mandiri accelerates digital banking for social innovation, enhancing security to protect customers from fraud is crucial. However, using a traditional public Network Time Protocol (NTP) clock server has not been accurate enough to meet industry-standard regulations, such as MiFID, for effective fraud prevention. Moreover, reliance on public NTP servers may result in greater visibility of Bank Mandiri’s network, which creates a need for enhanced vigilance and risk management.To address these challenges, NEC collaborated with its global partner Adtran to deploy the OSA 5412, a versatile NTP clock server designed for precise time synchronization with upgradeability to support Precision Time Protocol (PTP). As dedicated NTP servers in data centers, OSA 5412 provide increased accuracy and reliability for important activities such as transaction reporting, effectively meeting banking regulations for traceability and enhanced customer security. Moreover, this solution offers advanced jamming and spoofing detection to safeguard against cyber threats.Bank Mandiri’s adoption of NEC’s Network Transformation Service and Adtran’s Oscilloquartz time synchronization technology positions the bank at the forefront of digital banking in Indonesia, setting a new benchmark for security and operational excellence. Moving forward, NEC is committed to supporting the evolving needs of the banking industry and driving the advancement of secure digital banking."Bank Mandiri remains dedicated to driving digital innovation that enhances both customer satisfaction and security. Through our collaboration with NEC and Adtran, we have transformed our time synchronization capabilities, ensuring greater transaction traceability and operational reliability. As a digital pioneer in Indonesia's banking sector, we will continue to lead with innovation—leveraging AI and cutting-edge digital technologies to deliver trusted, future-ready financial services for our customers."- Denny Dwi Mavianto – Team Leader Bank Mandiri"Precise and secure time synchronization is essential to building trust in digital banking. Our OSA 5412 platform delivers industry-leading accuracy, resiliency and advanced security features, such as jamming and spoofing detection. This deployment not only meets global regulatory standards but also strengthens Bank Mandiri’s foundation for secure, real-time financial services in today’s dynamic digital economy."- Stuart Broome, GM of EMEA and APAC sales at Adtran."We are honored to support Bank Mandiri in elevating its digital infrastructure through our advanced network transformation and time synchronization solutions, in partnership with Adtran. NEC has long been dedicated to driving digital innovation in the banking sector by modernizing critical infrastructure, and we remain committed to delivering new advancements. We look forward to empowering financial institutions like Bank Mandiri to drive innovation and achieve business success in the AI and digital era."- Masayuki Kayahara, Corporate SVP, Global Network Division, NEC CorporationAbout NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries ACN Newswire

NEC and ClimateAi sign a Memorandum of Understanding (MoU) for business co-creation to enhance climate resilience across various industries

TOKYO, Dec 12, 2025 - (JCN Newswire via SeaPRwire.com) - NEC Corporation (NEC; TSE: 6701) and ClimateAi, Inc. have signed a Memorandum of Understanding (MoU) for the co-creation of business opportunities aimed at enhancing resilience against the impacts of climate change across multiple industries.By integrating ClimateAi's climate adaptation and risk forecasting technology with NEC's expertise in agritech, AI, data analysis, and optimization, the two companies aim to build solutions that directly support climate adaptation decision-making at the farm, corporate, financial, and governmental levels.BackgroundThe progression of climate change is heightening physical risks to food security and corporate supply chains, such as agricultural production variability, logistic disruptions, and price fluctuation risks.However, visualizing the return on investment (ROI) of climate adaptation measures—and continuously monitoring their effectiveness over time—remains challenging, making it difficult to mobilize funds and optimally take preventive measures.In August 2025, NEC and ClimateAi collaboratively developed a concept model to quantify the effectiveness of adaptation strategies like irrigation, varietal changes, and planting schedule adjustments using AI, specifically targeting cacao and rice in Africa. The model demonstrated its potential to support adaptation finance, policy formulation, and on-the-ground agricultural planning. This achievement was presented at TICAD9 (*1) and COP30, generating strong market interest from international organizations, development banks, and industry stakeholders.This MoU aims to promote the co-creation of comprehensive climate resilience solutions spanning agricultural sites, corporate supply chains, finance, and insurance, with a view towards transitioning from the demonstration stage to commercial application.Areas of collaboration- Both parties agreed to collaborate on business development in the following areas:1. Analysis of the ROI for climate change adaptation measures in the agricultural sectorBy combining ClimateAi's long-term climate change prediction technology with NEC's expertise in the agritech business, the companies aim to develop a service that analyzes yield, risk exposure, and the investment effectiveness of climate adaptation measures, such as crop changes and irrigation facility introductions.Considering the varying impacts of climate change on different lands, the goal is to analyze optimal adaptation measures from an economic perspective and support the advancement of agricultural assistance by international organizations, development banks, and governments.2. Enhancing supply chain resilience from the viewpoint of climate change adaptationTargeting the downstream agricultural sector, namely manufacturing industries that use agricultural products as main raw materials (such as food and beverage manufacturing), NEC and ClimateAi aim to support supplier optimization and improve resilience across upstream farms and supply networks to achieve services that support industrial adaptation to climate change.This technology can also support supply chain and procurement planning decisions across any industrial supply chain.3. Digital solutions for other sectors, including financial services and insuranceThe companies will explore the enhancement of financial services needed for climate adaptation-such as agricultural insurance-and identify new use cases for climate adaptation data across additional industries.Comments from each companyNaohisa Matsuda, Senior Director, Future value co-creation department / Business innovation division, NEC"NEC is delighted to announce an agreement on business development in collaboration with ClimateAi. By combining ClimateAi's strength in climate risk prediction and analysis with NEC's AI and data utilization capabilities and societal implementation prowess, we are confident that we can contribute to enhancing the resilience of supply chains and infrastructure while promoting climate change adaptation."Under the philosophy of ‘NEC Open Innovation,’ we are advancing the creation of new social value with diverse partners.Moving forward, through our collaboration with ClimateAi, we aim to accelerate implementation both domestically and internationally, centering on visualizing the impacts of climate change and advancing decision-making to co-create a sustainable society."Himanshu Gupta - CEO, ClimateAi"NEC’s global network and field partnerships open the door to implementing climate adaptation where it’s needed most. We’re energized by the work ahead—supporting organizations with agricultural planning, strengthening supply-chain resilience, and building practical solutions that can be deployed quickly and at scale. This collaboration also enables us to bring climate-informed insights into supply-chain and procurement planning, helping industries make better decisions as climate pressures grow."Future prospectsUnder the MoU, both companies will define priority regions, crops, and customer segments, and strengthen collaboration with international organizations, development banks, local partners, food manufacturers, trading companies, and financial and insurance institutions to advance early commercialization.NEC and ClimateAi aim to contribute to sustainable agriculture, food security, and greater industrial resilience.NEC’s new business development, under the key message "The future is ours to shape," is advancing NEC Open Innovation (*3) through diverse co-creation with a wide range of startups and partner companies. NEC’s collaboration with ClimateAi is one such initiative. By uniting innovative technologies with cross-domain collaboration, NEC continues to create new social value and shape the future.(*1) NEC to participate in "TICAD Business Expo and Conference" and thematic events for TICAD 9https://www.nec.com/en/press/202508/global_20250805_03.html(*2) NEC Lectures on "Strengthening Supply Chain Resilience through Digital Technologies" at COP30 Seminar Hosted by the Ministry of the Environment (Press Release in Japanese) https://prtimes.jp/main/html/rd/p/000001139.000078149.html(*3)https://www.nec.com/en/global/innovation/index.htmlAbout ClimateAi, Inc.ClimateAi is a climate adaptation and resilience platform purpose-built for the agriculture, food, and consumer goods sectors. It combines AI-powered weather modeling with phenological and water-scarcity data to deliver highly localized, crop-specific agricultural impact insights across the short, medium, and long term. With deep expertise in climate–agriculture interactions and a client base that spans agricultural and consumer-goods multinationals as well as agricultural investors, ClimateAi turns complex climate data into actionable insights. For more information, visit ClimateAi at https://www.climate.ai.About NEC CorporationNEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of “Orchestrating a brighter world.” NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at https://www.nec.com. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion ACN Newswire

2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten ACN Newswire

Everest Medicines Announces Commercialization Service Agreement and License Agreement with Hasten

HONG KONG, December 12, 2025 - (ACN Newswire via SeaPRwire.com) – Everest Medicines announced on Dec. 11, 2025 that its wholly-owned subsidiary, Everest Medicines (China) Co., Ltd (“Everest Medicines China”), has entered into two strategic agreements with privately held Hasten Biopharmaceutical Co., Ltd. (“Hasten”). The first is a Commercialization Services Agreement leveraging Everest's existing sales and marketing organization to provide commercialization services for a portfolio of Hasten's mature assets.The second is a License Agreement granting Everest the exclusive license to develop, register and commercialize Lerodalcibep, a novel, small protein-binding, third-generation PCSK9 inhibitor, which is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH) in Greater China.The two agreements are expected to create significant financial and strategic synergies, enhancing the operational efficiency of Everest’s existing commercial platform and accelerating the build-out of life-cycle and multi-channel commercialization capabilities. At the same time, they establish an attractive strategic footprint for the Company in the cardiovascular disease area. Through this collaboration, Everest will further strengthen its commercial foundation in China, expand market share, and inject core momentum into the long-term growth of its cardiovascular business. The potential approval of Lerodalcibep in Greater China in 2027 is expected to contribute to future revenue growth within Everest's cardiovascular portfolio.Commercialization Synergies to Strengthen Competitiveness Across a Multi-Product PortfolioEverest Medicines China will receive service fees from Hasten calculated by multiplying the net sales of each product for the applicable quarter by the applicable rate, which ranges from 20% to 55%. The proposed maximum annual caps for the transactions contemplated to be paid by Hasten for the three years ending December 31, 2028 are set at RMB 560 million in 2026, RMB 616 million in 2027, and RMB 677 million in 2028.The Commercialization Service Agreement covers six mature, commercially available products across three major therapeutic areas—critical care, cardiovascular disease, and metabolic disorders—including Rocephin(R), Stilamin(R), and Ebrantil(R) in critical care; Edarbi(R) and Blopress(R) in cardiovascular disease; and Basen(R) in metabolic disease. The portfolio is highly synergistic with Everest’s existing commercial infrastructure and strategic focus. Among them, the three core critical care products—Rocephin(R), Stilamin(R), and Ebrantil(R)—play an essential clinical role in the treatment of infectious, gastrointestinal emergency, and cardiovascular emergency conditions. Rocephin(R), for example, is a broad-spectrum, third-generation cephalosporin that has achieved coverage in more than 8,500 hospitals nationwide and holds over 80% market share, maintaining strong and sustained clinical demand in the treatment of complex infections. Notably, these transactions are expected to generate significant synergies for Everest by aligning XERAVA(R) with Hasten’s critical care portfolio — including Rocephin(R) and Stilamin(R) — across complementary geographic footprints, channel access and hospital coverage, while further strengthening the Company’s commercialization capabilities and life-cycle management of innovative medicines.With the addition of this product portfolio, the Company’s commercial presence in key therapeutic areas such as critical care and cardiovascular diseases will be further expanded, creating stronger synergies with its existing commercialization organization and providing more robust support for the scaled development and revenue growth of its commercial platform.Introduction of Lerodalcibep to Expand Strategic Footprint in Cardiovascular DiseasesThe agreement grants Everest the exclusive license to develop, register and commercialize Lerodalcibep in Greater China, together with a royalty-free, exclusive license to use Hasten's trademarks for the product in the territory. Pursuant to the license agreement, Everest Medicines China will make an initial payment of US$29 million (approximately RMB 205 million), and may pay up to US$30 million (RMB 212 million) in potential development and regulatory milestone payments and up to US$280 million (RMB1977 million) in potential sales milestones, in addition to royalties based on the total, aggregate annual net sales.Lerodalcibep, developed by privately-held and U.S.-based company LIB Therapeutics, is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH). Lerodalcibep is a novel, small protein-binding, third-generation PCSK9 inhibitor, and has been developed as a more patient friendly and convenient, once-monthly, single small-volume, subcutaneous injection that will not require refrigeration at home or in travel. These features make Lerodalcibep a unique alternative to approved PCSK9 inhibitors. In large, global phase 3 clinical trials in over 2,500 patients, Lerodalcibep has demonstrated sustained LDL-C reductions of >60% in patients with, or at very-high or high risk of, cardiovascular disease (CVD) and >55% in those with heterozygous familial hypercholesterolemia (FH) who have more severe LDL-C elevations. In addition, the head-to-head LIBerate-VI study, comparing Lerodalcibep with Inclisiran, demonstrated the superiority of Lerodalcibep (p=0.0319). Lerodalcibep is expected to expand treatment options for the millions of patients around the world with CVD, including the 30 million individuals with FH. These LDL-C reductions have been confirmed in a recent phase 3 clinical trial in a Chinese population with, or at very high risk of, CVD including FH.Multiple PCSK9 inhibitors are currently approved and marketed in China, with a combined market size of approximately RMB 3 billion and year-over-year revenue growth of 95% in 2024. The market is expected to further increase to approximately RMB10 billion in 2030, according to a Frost & Sullivan report. Despite an estimated 400 million individuals in China with dyslipidemia, only ~14% receive lipid-lowering treatment, reflecting low penetration and significant unmet medical need. Lerodalcibep has patent exclusivity in China through 2039.Lerodalcibep is currently under regulatory review by both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). In Greater China, Biologics License Application (BLA) submission is expected in 1H 2026, with the potential for approval in 2027.Everest considers Lerodalcibep an important future growth driver and a key addition to its innovative medicines portfolio. The transaction is viewed as aligned with the Company’s strategy to focus on high-potential therapeutic areas and to expand its late-stage pipeline through business development collaborations, thereby strengthening its overall portfolio.Market commentators note that the two agreements provide both near-term revenue contribution and clear longer-term growth opportunities. By leveraging its established medical, market access, marketing and sales capabilities, Everest is expected to improve the efficiency of its commercial operations and resource utilization, while further demonstrating the scalability and resilience of its commercial platform. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition ACN Newswire

Anime Tokyo Station: A Series of Linked Events to Be Held in Conjunction with the Anniversary Joint Exhibition

TOKYO, Dec 12, 2025 - (JCN Newswire via SeaPRwire.com) - Anime Tokyo Station, an exhibition center for Japanese anime operated by the Tokyo Metropolitan Government and the Association of Japanese Animations, has welcomed 240,384 visitors from Japan and overseas (as of November 30, 2025) as a facility that promotes the appeal of Japanese anime to the world under the motto “Making ANIME more interesting, Bringing ANIME far into the future.”We are pleased to announce that a variety of events will be held in conjunction with the ongoing “Digimon Adventure 02” & “Magical DoReMi #” ANIME 25TH ANNIVERSARY JOINT EXHIBITION.As part of the monthly “Anime Watch Party” held at Anime Tokyo Station, a special winter event will feature screenings of “Digimon Adventure 02” and “Magical DoReMi #.” An event screening the first episodes of both titles will take place on Sunday, December 21, 2025. To commemorate the occasion, a special guest may also make an appearance.In the Special Lecture Series “The Power to Create Anime: Nine Lessons for the Future,” where attendees can listen, learn, and gain insight into the anime industry through the words of leading professionals, Hiroyuki Kakudo, the series director of Digimon Adventure 02, will appear in Session 4, and Hiromi Seki, the producer of Magical DoReMi #, will appear in Session 5. This event offers a rare opportunity to hear valuable stories—including on-site experiences and behind-the-scenes episodes of anime production—at Anime Tokyo Station, a facility dedicated to sharing the appeal of anime.In addition, meet-and-greet events featuring characters from “Digimon Adventure 02” and “Magical DoReMi #” have been confirmed. On Sunday, January 25, 2026, Doremi-chan from Magical DoReMi # will make an appearance, and on Sunday, February 1, 2026, Veemon from Digimon Adventure 02 will appear. Why not enjoy the exhibitions while also taking commemorative photos to capture your memories?The latest updates on each event are available on the official website and social media accounts. We invite you to experience the world of Digimon Adventure 02 and Magical DoReMi # here at Anime Tokyo Station, a facility dedicated to sharing the appeal of anime.“Anime Watch Party 12” – Winter Special Event Details“Anime Watch Party 12” – Winter Special Event(1) Date and time: Sunday, December 21, 20251. 13:00–14:25 Magical DoReMi # — Talk & Giveaway Quiz Contest2. 15:00–16:00 Digimon Adventure 02 — Talk & Giveaway Quiz Contest3. 16:30–17:00 Magical DoReMi #4. 17:30–18:00 Digimon Adventure 02A special guest may also make an appearance on the day.For the latest updates, please check the official website, social media accounts, and in-facility announcements.*Noriko Namiki will be present at (1) and (2).*Anime screening only at (3) and (4).(2) Venue: 1st Floor (in front of Interactive Vision), Anime Tokyo Station (Tokyu East 5, 2-25-5 Minami-Ikebukuro, Toshima City, Tokyo)(3) Films to be screened"Digimon Adventure 02" – Episode 1: The Inheritor of CourageStory summaryThe Digimon Kaiser suddenly appears in the once-peaceful Digital World, bringing suffering to Agumon and the others. Taichi heads to the Digital World to save them, but he finds himself in danger when the Kaiser’s power prevents Agumon from evolving. Upon learning that Taichi is in trouble, Takeru and the others attempt to head for the Digital World. At that moment, a Digivice appears in the hand of Daisuke, who is with them. And when Daisuke touches the Digi-Egg of Courage—an egg no one had ever been able to move—the curtain rises on a brand-new adventure.“Magical DoReMi #” – Episode 1: Doremi Becomes a Mom!?Story summaryThe Ojamajo girls head to the Witch World to deliver something Majolica forgot, but they accidentally wander into the Queen’s garden, where they witness a baby being born from a single rose.According to the rules of the Witch World, the person who first sees the newborn baby must take care of it for one year. And so, a new chapter in the Ojamajo girls’ lives begins.(4) Event Navigator: Noriko Namiki (voice actress)(5) No. of participants: Approximately 30 (come and go as you wish)(6) Participation fee: Free*Please sit in the allocated seating area.*Photos, video recordings, and sound recordings inside the venue are prohibited on the day of the events.*Guests may be required to stand if all the seats are filled.*Seats may be moved after each screening.*Staff will take photographs for use in Anime Tokyo Station publicity and reporting materials.By participating, it is assumed that you understand and agree to these conditions.*Please follow staff guidance when participating.For details, please visit https://animetokyo.jp/en/archives/events/events52/Details of the Special Lecture Series “The Power to Create Anime: Nine Lessons for the Future”(1) Date and time:Session 4 —Saturday, December 20, 2025, 15:00–17:00Hiroyuki Kakudo (Animation Director, known for Digimon Adventure 02)Application: https://forms.office.com/r/aJpjFwdfeVSession 5 —Saturday, January 17, 2026, 15:00–17:00Hiromi Seki (Producer, Planning Department, Toei Animation; known for Magical DoReMi #)Application: Please check the official website.*Please note that session times are subject to change.(2) Venue: Special Event Hall, 14th Floor, Anime Tokyo Station (Tokyu East 5, 2-25-5 Minami-Ikebukuro, Toshima City, Tokyo)(3) Participation fee: Free(4) Eligible age: High school students and above*Non-Japanese nationals who understand Japanese are also eligible to participate.(5) No. of participants: 50 per session (advance application and lottery)(6) How to apply: Please apply for each session via the application URL provided on the event page of the Anime Tokyo Station official website.Event page: https://animetokyo.jp/en/archives/events/workshop50/*Please check each session’s application page for the application deadline.*Please read the notes on the application page before applying.*For cancellations or related inquiries, please contact us at the email address below.Contact: info@animetokyo.jpCharacter Meet-and-Greet Details“Magical DoReMi #” — Doremi-chan(1) Schedule:January 25, 2026 (Sun.)(2) Time:Session 1: 12:00–12:20Session 2: 14:00–14:20Session 3: 16:00–16:20(3) Venue:1st floor, Anime Tokyo Station(4) No. of participants:One group of 20 persons per session(5) Application date:From December 19 (Fri.), 2025 “Digimon Adventure 02” — Veemon(1) Schedule:February 1, 2026 (Sun.)(2) Time:Session 1: 12:00–12:20Session 2: 14:00–14:20Session 3: 16:00–16:20(3) Venue:1st floor, Anime Tokyo Station(4) No. of participants:One group of 20 persons per session(5) Application date:From December 19 (Fri.), 2025 Notes- Date, time, and contents are subject to change.- Please check the official website and social media accounts for the application URL and the latest updates.- Please fill in the application after reading and understanding the notes on the application page.Venue OverviewName:Anime Tokyo Station (also known as "Anime Tokyo")Location:Floors B1 to 2F of Tokyu East 5 (2-25-5 Minami-Ikebukuro, Toshima-ku, Tokyo)*4 minutes on foot from Ikebukuro StationHours:11:00 a.m. to 7:00 p.m. (last admission: 6:45 p.m./ Special exhibitions close: 6:30 p.m.)Closed: Mondays*If Monday falls on a holiday, the venue will be open on Monday and closed on the following dayNew Year's holiday periodMay be closed on other daysPlease check the venue website before coming.Admission fee:FreeWebsite:https://animetokyo.jp/en/sns:X|https://x.com/animetokyo_info (@animetokyo_info)Instagram|https://www.instagram.com/animetokyostation/ (@animetokyostation)YouTube|https://www.youtube.com/@AnimeTokyoStationInquiries regarding this press releasePublic Relations Office of "Anime Tokyo Station" (Kyodo PR)Contact person: Miri YasudaE-mail: animetokyo-pr@kyodo-pr.co.jp Press release: http://www.acnnewswire.com/docs/files/20251212.pdf Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion ACN Newswire

HKTDC 4Q25 Export Confidence Index: 2026 Hong Kong Export Growth of 8-9%, Sustained AI product demand lays solid foundation for future expansion

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Hong Kong’s exports are expected to grow by between 8% and 9% in 2026, according to figures releaased today by the Hong Kong Trade Development Council (HKTDC). The forecast forms part of the HKTDC’s annual Export Outlook report and follows on from the city’s better-than-anticipated 2025 export performance.For 2026, this sustained growth is set to be driven by robust demand for AI-related electronics products. According to the findings of the recently-released HKTDC 4Q25 Export Confidence Index, the majority of exporters (53.2%) see rising demand for AI/new technology-related electronic consumer goods as the factor most likely to boost their 2026 business. This is seen as crucial given that the electronics sector, overall, accounts for more than 70% of Hong Kong’s total export value.Heightened uncertainty giving way to greater clarityThese upbeat figures are remarkable given the high year-on-year comparison base from 2025. This is because many exporters sought to frontload orders in a bid to complete shipments before the imposition of the much-anticipated US tariffs.Detailing the upshot of the tariff-related trade upheavals in particular, Irina Fan, Director of HKTDC Research, said: “While 2025 proved to be a year of heightened uncertainty, 2026 should be a year of greater clarity on global trade. With the Chinese Mainland and the US having come to a trade agreement in November, – some four months after many other nations had struck their own deals with the Trump administration – US tariffs are no longer among Hong Kong exporters' three biggest 2026 concerns.”Fan did, however, acknowledge that uncertainties remain ahead. She said that as US imports from different countries are subject to different levels of tariffs, business leaders around the world will be looking to re-organise their activities to optimise any cost advantages.Outlining what this will mean within the Asia-Pacific region, Fan said: “Chinese Mainland exports to the US will be subject to 20% reciprocal tariff rate until November 2026 [1]. This comparatively low additional tariff puts China-based suppliers, many with more mature and highly productive supply chains, on par with their Southeast Asia counterparts, while giving them a significant advantage over any country subject to a higher tariff rate.”Multi-sector expectation of continued export expansionUnderpinning Hong Kong’s anticipated 2026 export expansion are the findings of the HKTDC Export Confidence Index 4Q25, which was also released today. The two key measures of this long-established quarterly metric –the Current Performance Index (51.4) and the Expectation Index (51.9) – have both stayed above the 50-point watershed level, a clear indication that future export growth is expected.Commenting on the findings of the 4Q25 survey, Kenneth Lee, Head of the HKTDC Research’s Special Project and Business Advisory Section, said: “When it comes to expansion plans over the next two-year period, Asia remains very much the focus. For 42.0% of respondents, the Chinese Mainland was the highest priority market, followed by the rest of Asia (30.3%) and the ASEAN bloc (18.9%). By industry, exporters in almost every sector saw scaling up their activities on the Chinese Mainland as their priority.”Beyond the headline findings of the survey, a more detailed analysis highlights good news for Hong Kong exporters in terms of both individual market prospects and the likely future success of most of the city’s key industry sectors.Positive sentiments for major markets and key industry sectorsIn specific terms, turning to the Market Expectation Sub-Index, the Chinese Mainland (57.2) and the ASEAN bloc (57.0) are still considered to have significant growth potential. Predictably, this was less the case for the US (down 1.4 to 38.0), with the uncertainties in its trade environment continuing to unsettle Hong Kong exporters.Turning to individual industries, a number of sectors have expansionary expectations for the year ahead (i.e. had a relevant index reading of 50 or more). Topping the list is Jewellery (54.8), followed by Electronics (52.4), Timepieces (51.6) and Equipment/Materials (51.1).Despite such overall positive sentiments, the survey also points out the possibility that a number of challenges may lie ahead. Most notably, it cited rising labour and production costs (53.9%), growing logistics challenges (38.8%) and declining overseas orders on account of the general economic slowdown (38.2%) as potential future concerns.[1] On top of Trump 1.0 tariffs of ~20% on averageReferencesHong Kong 2026 Export Outlook: Sustained AI Product Demand Set to Drive 8-9% Growth Over Coming Year:https://research.hktdc.com/en/article/MjE4ODc2Mzk2NwHKTDC Export Confidence Index 4Q25: End-of-Year Figures Indicate Positive Expansion Prospects:https://research.hktdc.com/en/article/MjE4ODYyNTQwNwHKTDC Research website: https://research.hktdc.com/en/ Photo download: https://bit.ly/4oJPrPRHKTDC Director of Research Irina Fan (right) and HKTDC Section Head, Special Project & Business Advisory, Kenneth Lee (left) announced the HKTDC Export Confidence Index for 2025’s fourth quarter at a press conference todayHKTDC Director of Research Irina FanHKTDC Section Head, Special Project & Business Advisory Kenneth LeeMedia enquiriesPlease contact the HKTDC’s Communication and Public Affairs Department:Navin LawTel: (852) 2584 4525Email: navin.cm.law@hktdc.orgAgnes WatTel: (852) 2584 4554Email: agnes.ky.wat@hktdc.orgAbout HKTDCThe Hong Kong Trade Development Council (HKTDC) is a statutory body established in 1966 to promote, assist and develop Hong Kong's trade. With over 50 offices globally, including 13 in Mainland China, the HKTDC promotes Hong Kong as a two-way global investment and business hub. The HKTDC organises international exhibitions, conferences and business missions to create business opportunities for companies, particularly small and medium-sized enterprises (SMEs), in the mainland and international markets. The HKTDC also provides up-to-date market insights and product information via research reports and digital news channels. For more information, please visit: www.hktdc.com/aboutus. Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

SHENZHEN, Dec 11, 2025 – (ACN Newswire) – China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke. With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms. Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals. The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients. More Information about Y-3 for Injection The pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects. The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability. On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent. About Stroke According to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference 1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001. 2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010. CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/
More
CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China ACN Newswire

CMS (867/8A8): NDA of Innovative Drug Y-3 for Injection for Acute Ischemic Stroke Accepted in China

SHENZHEN, Dec 11, 2025 - (ACN Newswire via SeaPRwire.com) - China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 11 December 2025, the New Drug Application (NDA) of Class 1 Innovative Drug Y-3 for Injection (proposed English generic name: Loberamisal for Injection) (“Y-3 for Injection” or the “Product”) has been accepted by National Medical Products Administration of the People’s Republic of China (NMPA). The Product is a brain cytoprotectant indicated for the treatment of acute ischemic stroke.With well-defined targets and clear mechanism of action, Y-3 for Injection is able to exert multiple therapeutic effects. As the world’s first brain cytoprotectant developed based on the important targets PSD95-nNOS and MPO, in the pathological processes of stroke, Y-3 for Injection acts on multiple key pathological processes of the ischemic cascade in ischemic stroke. Through multi-target, highly selective synergy, it is more conducive to exerting brain cytoprotective effects. The Product has an excellent therapeutic effect on ischemic stroke and the potential to prevent post-stroke depression and anxiety symptoms.Y-3 for Injection demonstrates excellent clinical data with excellent efficacy and a favorable safety profile. The results of Phase II clinical trial of the Product in China indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (40mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group, with a rate difference of 16%. The Phase III clinical trial of the Product in China was conducted by Beijing Tiantan Hospital, Capital Medical University as the leading site. It has enrolled nearly 1,000 patients with acute ischemic stroke within 48 hours of onset across approximately 40 research centers nationwide, aiming to evaluate the efficacy and safety of Y-3 for Injection in treating patients with acute ischemic stroke within 48 hours of onset. The Phase III clinical study met the primary efficacy endpoint, with patients achieving significant clinical benefits and an overall favorable safety profile. The key study results are planned to be presented at international academic conferences, and the full study will be published in international academic journals.The Central Nervous System (CNS) is one of the core advantageous fields of CMS, where a deeply integrated layout has been progressively established. The product portfolio has solidified the market foundation, including the marketed innovative drug VALTOCO (Diazepam Nasal Spray), the original brand drug Deanxit (Flupentixol and Melitracen Tablets), and the improved new drug ZUNVEYL (Benzgalantamine Gluconate Enteric-coated Tablets), which is currently under NDA review. The addition of Y-3 for Injection will further strengthen the product portfolio, generating highly efficient synergies in terms of expert networks and market resources. It is expected that if approved for marketing, Y-3 for Injection will bring a new generation of brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects to Chinese patients with ischemic stroke. Leveraging the successful commercialization experience and compliant and efficient operation system, the Group will accelerate the accessibility of innovative therapies to benefit more patients.More Information about Y-3 for InjectionThe pathological processes of acute ischemic stroke are highly complex and interconnected. There is an urgent clinical need for multi-target, multi-mechanism coordinated interventions to achieve more effective regulation of the complex ischemic cascade, thereby improving treatment outcomes and enhancing patients’ quality of life. Y-3 for Injection is able to uncouple PSD95-nNOS, inhibit MPO activity, and enhance the activity of α2-GABAA receptor (a subtype of GABAA receptor with antidepressant and anxiolytic effects). With this multi-target, highly selective synergistic mechanism, it is expected to achieve a technological breakthrough in the simultaneous intervention of “stroke treatment and prevention of post-stroke depression and anxiety”, making Y-3 for Injection a promising novel brain cytoprotectant with excellent efficacy and more comprehensive therapeutic effects.The results of Phase II clinical trial of Y-3 for Injection for the treatment of acute ischemic stroke were presented as an oral poster at the 10th European Stroke Organisation Conference in 2024 (ESOC 2024). It indicated that among patients with ischemic stroke within 48 hours of onset, patients in the Y-3 group (20mg, 40mg, 60mg, qd) demonstrated a significantly higher proportion of patients achieving an excellent functional outcome (mRS of 0-1) at 90 days than those in the placebo group (20mg: 67.8% vs 60.7%, 40mg: 76.7% vs 60.7%, 60mg: 70.0% vs 60.7%). Moreover, the Product showed comparable safety to placebo in acute ischemic stroke patients, exhibiting good tolerability.On 24 August 2023, the Group through its wholly-owned subsidiary entered into a Collaboration Agreement (the “Agreement”) with Neurodawn Pharmaceutical Co., Ltd. (“NeuroDawn”), a clinical needs-oriented pharmaceutical company driven by innovation and R&D. In accordance with the Agreement, the Group obtains an exclusive promotion right in mainland China, the Hong Kong Special Administrative Region, and the Macau Special Administrative Region. The term of the Agreement is permanent.About StrokeAccording to the Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) issued by the National Health Commission, approximately 3.94 million new stroke cases occur in China each year, accounting for one-third of the global new cases[1]. Among these, ischemic stroke accounts for about 72%, with over 2.8 million new cases annually; the number of existing stroke patients in China has exceeded 28 million[1]. Data from China’s cause-of-death monitoring in 2021 shows that stroke-related deaths accounted for 23% of the national total deaths[1]. Over the past three decades, the disease burden of stroke-related disabilities in China has continued to increase[1]. Coupled with factors such as the accelerating aging of the population, the pressure of stroke prevention and control will further intensify in the future, posing enormous challenges to patients’ families and society[1]. In addition, post-stroke depression and anxiety are common complications of stroke, with incidence rates of approximately 30% and 25% respectively[2]. They can hinder the recovery of patients’ neurological functions, even increase the risk of death, and severely affect patients’ prognosis. Y-3 for Injection holds significant potential value for the long-term neurological function improvement and overall prognosis of a vast number of stroke patients, indicating broad market prospects.About CMSCMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs.CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients.CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group.Reference1. National Health Commission of the People’s Republic of China. Guideline for Prevention and Treatment of Cerebrovascular Disease (2024 Edition) [J]. Chinese Journal of Magnetic Resonance Imaging, 2025, 16(1): 1-8. DOI: 10.12015/issn.1674-8034.2025.01.001.2. Chen Xinyu, Lyu Xiaohan, Li Ruina, et al. Post-Stroke Anxiety [J]. International Journal of Cerebrovascular Disease, 2022, 30(2): 129-133. DOI: 10.3760/cma.j.issn.1673-4165.2022.02.010.CMS Disclaimer and Forward-Looking StatementsThis press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert.This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections.Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/ Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Eisai Rated “A”, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year ACN Newswire

Eisai Rated “A”, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

TOKYO, Dec 11, 2025 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) has announced that it has been selected for the highest-rated “A” List in the fields of Climate Change and Water Security for 2025 by the global environmental non-profit organization CDP.(1) This marks the second consecutive year the company has been named in both categories of the CDP’s A List.Based on Eisai’s Future Creation Strategy(2) (Sustainability Strategy), the company is committed to addressing material issues and social challenges over the mid- to long- term, with the aim of contributing to sustainable corporate growth and the sustainable development of society. In the field of environmental conservation, Eisai has identified “Business activities with consideration for the global environment” as one of our material issues. Based on the Eisai Network Companies Environmental Policy, Eisai is promoting responses to climate change and sustainable water use as environmental activities across the group.As part of its climate change response, Eisai is working towards the realization of a decarbonized society, including obtaining approval for the SBT 1.5'C target from the Science Based Targets (SBT) Initiative in FY2023, and participating in the Japan Climate Initiative (JCI) Race to Zero Circle, which calls for achieving net zero by 2050. Through these efforts, Eisai is contributing to the reduction of greenhouse gas emissions.(3) Regarding sustainable water use, Eisai has set its mid-term target to reduce water withdrawal across the company by 7%(4) by FY2030 compared to FY2023, promoting efficient use of water resources, including recycling of laboratory wastewater and rainwater. Please refer to Eisai’s website for more detailed information about its environmental activities.To realize the human health care (hhc) concept, conservation of the global environment is essential. Eisai is committed to empowering people to “realize their fullest lives” through initiatives addressing climate change and the promotion sustainable water use.(1) A non-profit organization headquartered in the UK. The organization operates the world’s only independent environmental information disclosure system(2) Please refer to Eisai Value Creation Report (https://www.eisai.com/ir/library/annual/pdf/pdf2025vcr.pdf)(3) Please refer to the following news release for details. EISAI TO BOOST INITIATIVES ON GREENHOUSE GAS REDUCTION, AIMING TO ACHIEVE NET ZERO BY 2050 (https:/www.eisai.com/news/2024/news202412.html)(4) Per unit of salesMedia Inquiries:Public Relations Department,Eisai Co., Ltd.+81-(0)3-3817-5120 Copyright 2025 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com
More
Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing ACN Newswire

Focus Graphite Achieves 99.9996 wt.% Ultra-High Purity and 2.03 ppm EBC in Follow-On Testing

5N+ Purity and On-Spec EBC Confirm Lac Knife's Potential as a North American Source of Ultra-High-Performance Graphite ApplicationsOttawa, Ontario--(ACN Newswire via SeaPRwire.com - December 11, 2025) - Focus Graphite Inc. (TSXV: FMS) (OTCQB: FCSMF) (FSE: FKC0) ("Focus" or the "Company") a Canadian developer of high-grade flake graphite deposits and innovator of next-generation battery technology, is pleased to announce that follow-on purification and elemental analysis of material from its Lac Knife deposit (concentrate Lot ID: GN25073005) achieved 99.9996 wt.% ("5N+") and an Equivalent Boron Concentration ("EBC") of 2.03 ppm, confirming the material is within nuclear-grade specification and meets the technical thresholds required for several high-value advanced materials markets.The test work, conducted using electrothermal purification with no halogen gases (e.g. chlorine) or acids, produced this ultra-pure result in two (2) hours, further validating a chemical-free, environmentally advantageous pathway compared to conventional purification methods. These results directly support Focus's ongoing engineering and scale-up programs funded under Natural Resources Canada's ("NRCan") Global Partnerships Initiative ("GPI"), under which the Company was awarded a non-repayable contribution of up to $14.1 million to accelerate North American capacity for clean, advanced material processing.Subsequent elemental analysis calculated in accordance with ASTM C1233-15: Standard Practice for Determining Equivalent Boron Contents of Nuclear Materials yielded an Equivalent Boron Concentration ("EBC") of 2.03 ppm (Table 1), which falls below the critical 3 ppm threshold often cited for nuclear-grade graphite applications. The calculated EBC value is the most critical test of purity for nuclear industry use.These results suggest that Lac Knife graphite has the potential to serve markets requiring ultra-high-purity large and jumbo flake natural graphite. Achieving both 5N+ purity and a high proportion of large-flake concentrate is uncommon in the natural graphite industry and may provide Focus with opportunities in markets historically reliant on synthetic graphite or otherwise inaccessible to peers. These findings are consistent with peer-reviewed research published in ACS Omega ("Ultrahigh Temperature Purification of Graphite for the Development of a Continuous Process," ACS Omega, 2025), conducted by American Energy Technologies Company ("AETC") and NRCan, which demonstrated that ultrahigh-temperature purification of natural Canadian graphite can produce materials exhibiting purity and crystallinity suitable for advanced applications. Focus's ongoing testwork indicates that residual impurities appear primarily on the surface of the graphite flake—as evidenced by ultra-fine features observed through scanning electron microscopy—suggesting that purification efficiency is strongly influenced by surface cleaning dynamics rather than structural defects within the carbon lattice.Dean Hanisch, Chief Executive Officer of Focus commented, "These results validate Lac Knife as one of the rare unique natural graphite deposits capable of competing in high margin advanced technological markets and as a potential alternative to synthetic materials that are more expensive and have a larger environmental impact. With support from Canada's Federal Government, through Natural Resources Canada's Global Partnerships Initiative, we are now positioned to accelerate our scale-up work and unlock commercial pathways across nuclear energy, defense systems, graphene production, and next-generation electronics."Lac Knife graphite's combination of ultra-high purity and large flake distribution positions it for a range of advanced industrial, clean energy, and high-technology applications.Unlocking Advanced Markets Beyond NuclearBeyond nuclear applications, the ultra-high purity and medium-grain morphology of Lac Knife graphite position the material as a strategic feedstock for several advanced technology markets facing supply shortages, performance bottlenecks, and increasing scrutiny over material purity.Graphene & Few-Layer Graphene (FLG) ProductionIn the graphene sector, precursor quality is the primary determinant of performance. Impurities commonly found in natural graphite—typically 0.5-1 microns in size, or roughly one thousand (1000) times thicker than a graphene layer—are known to disrupt electrical, thermal, and mechanical properties unless fully removed. Lac Knife's 5N+ purity eliminates these defects at the source, allowing the flake to exfoliate cleanly into high-value graphene structures.Peer-reviewed research published in Carbon ("Influence of graphite geography on the yield of mechanically exfoliated few-layer graphene," Carbon, 2023) demonstrates the significance of geological origin in FLG production. In follow-on AETC—Yale University testing based on the methodologies outlined in that study, Lac Knife graphite achieved a record-high few-layer graphene yield of 22% ± 3%, outperforming all other natural samples evaluated and showing exfoliation behavior that synthetic graphite could not replicate.Taken together, these results position Lac Knife as one of the few North American natural flake sources capable of supplying advanced graphene markets, including conductive coatings, EMI-shielding materials, flexible electronics, sensors, and next-generation energy storage systems.Defence: IR Obscuration & Countermeasure SystemsThe defence sector presents another major opportunity. Modern warfare increasingly requires materials capable of obscuring both visible and infrared signatures. Traditional obscurants—such as bronze flakes, titanium dioxide, and red phosphorus—pose toxicity, safety, and performance challenges. High-purity graphite and graphene derived from Lac Knife offer a lightweight, non-toxic, and thermally stable alternative capable of generating rapid-dispersion and longer-lasting obscurant clouds.These materials are applicable to 40 mm muzzle-blast cartridges, airburst obscuration rounds for UAVs and rotorcraft, countermeasure dispenser systems, and naval surface-ship defence platforms. The U.S. Department of War currently procures graphene-based obscurants at approximately US$30,000 per ton, reflecting both strategic importance and limited supply. Lac Knife's purity is essential here, as impurities directly interfere with graphene formation and degrade obscurant performance.Stealth Coatings & Electromagnetic Protection SystemsUltra-high purity graphite also plays a critical role in stealth coatings and electromagnetic protection systems. Engineered systems operating across the 400 MHz to 30 GHz spectrum require materials that deliver highly reproducible electrical conductivity, thermal stability, and particle uniformity.These coatings and composites are used in radar-absorbing structures for stealth UAVs, thermal-vision targeting systems, and a range of low-observable technologies. Because deviations in graphite purity can compromise system reliability or operator safety, defence and shielding markets pay substantial premiums—often up to US$50,000 per ton—for 5N-grade material. Lac Knife's combination of purity, consistency, and grain structure aligns closely with these stringent requirements and allows for further refinement into fine, superfine, ultrafine, or microfine grades without compromising integrity.Critical Infrastructure Hardening (HEMP, IEMI and Geomagnetic Storms)The same purity advantages extend into critical infrastructure protection. As governments and utilities work to harden electrical grids, substations, and 5G networks against high-altitude electromagnetic pulses (HEMP), intentional electromagnetic interference (IEMI), and severe geomagnetic storms, materials must perform reliably across high-frequency ranges and under extreme operating conditions.Graphite-based shielding and coatings designed for these systems rely on predictable, reproducible material behavior—standards that only ultra-high purity graphite can meet. Lac Knife's 5N+ output offers the reliability required for these mission-critical applications.Additional High-Value Markets Enabled by 5N+ PurityIn addition to these strategic sectors, Lac Knife's purity profile and particle characteristics also unlock potential in several high-value industries, including thermal management components for semiconductors and LEDs, high-pressure synthetic diamond production, PEM and SOFC fuel-cell bipolar plates, and laboratory-grade graphite consumables where contamination must be tightly controlled. In each of these markets, ultra-high purity reduces defects, increases stability, and improves overall system performance, enabling natural graphite to compete directly with synthetic alternatives.Next Steps in Technical ValidationFocus is advancing a comprehensive technical qualification program to further define Lac Knife's suitability for nuclear and advanced material markets. Ongoing nuclear graphite testing includes detailed characterization of particle size distribution, compressibility, electrical resistivity, and coefficient of friction—parameters that determine whether a graphite material can perform reliably under the thermal, mechanical, and irradiation stresses present in high-temperature reactor environments. The Company expects to fabricate and evaluate near-net-shape graphite bricks, an essential step toward assessing Lac Knife material in full-scale core component geometries and within ASME Division 5 design criteria.In parallel, Focus is extending its validation program—supported through NRCan's Global Partnerships Initiative ("GPI")—advanced materials markets. Current work programs under consideration include assessing Lac Knife graphite as a precursor for high-yield graphene, nano-wafer substrates, thin-film semiconductors, next-generation electronic components, and aerospace composites, including unmanned aerial systems (UAS). These sectors demand highly reproducible, ultra-high-purity carbon materials traditionally sourced from synthetic graphite. Early results indicate that Lac Knife's 5N+ natural graphite may offer a technically competitive—and potentially more sustainable—North American alternative to synthetic feedstocks across multiple high-value applications.ElementImpurity Limit (mg/kg)EBC FactorEBC CalculationAg0.050.00830.000415Al10.00010.0001B0.1210.12Ca0.360.00020.000072Cd50.31721.586Cl1.50.01340.0201Co0.050.00890.00445Cr0.120.00080.000096Cu0.250.00080.0002Dy0.050.08180.00409Eu0.10.4250.0425Fe0.210.00060.000126Gd0.054.39910.219955K0.60.00080.00048Li0.030.14390.004317Mn0.120.00340.000408Mo0.150.00040.00006Na0.0850.00030.0000255Ni0.180.00110.00198S1.40.00020.00028Si1.460.00010.000146Sm0.050.53360.02668Th0.010.00050.000005Ti0.530.00180.000954U0.050.00050.000025V0.080.00140.000112 Total 2.0277895 Table 1: EBC Calculation, Thermally Purified Lac Knife Lot ID: GN250730005Figure 1: Particle Size Distribution, Thermally Purified Lac Knife Lot ID: GN250730005To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/1963/277711_279dc9a07490cbe0_001full.jpgTap DensityScott VolumeSurface AreaLOI g/ccg/ccm2 /gWt. % C0.60.41.499.9996 Table 2: Data, Thermally Purified Lac Knife Lot ID: GN250730005% TileSize (um)D10105.2D50337.3D90673.8MV368.5 Table 3: Data (2), Thermally Purified Lac Knife Lot ID: GN250730005Qualified PersonDr. Joseph Doninger, Director of Technology and Manufacturing for Focus Graphite, is the Qualified Person ("QP") as defined under National Instrument 43-101 - Standards of Disclosure for Mineral Projects. Dr. Doninger has reviewed and approved the technical information contained in this news release. Dr. Doninger is a chemical engineer and the developer or co-developer of multiple U.S., European, and Canadian patents relating to carbon processing technologies and purification equipment. He has authored or co-authored more than two dozen technical papers and studies on graphite composite anodes, carbon-based materials for electrochemical energy storage systems, and advanced graphite for lithium-ion batteries.About Focus Graphite Advanced Materials Inc. Focus Graphite Advanced Materials is redefining the future of critical minerals with two 100% owned world-class graphite projects and cutting-edge battery technology. Our flagship Lac Knife project stands as one of the most advanced high-purity graphite deposits in North America, with a fully completed feasibility study. Lac Knife is set to become a key supplier for the battery, defense, and advanced materials industries.Our Lac Tetepisca project further strengthens our portfolio, with the potential to be one of the largest and highest-purity and grade graphite deposits in North America. At Focus, we go beyond mining - we are pioneering environmentally sustainable processing solutions and innovative battery technologies, including our patent-pending silicon-enhanced spheroidized graphite, designed to enhance battery performance and efficiency.Our commitment to innovation ensures a chemical-free, eco-friendly supply chain from mine to market. Collaboration is at the core of our vision. We actively partner with industry leaders, research institutions, and government agencies to accelerate the commercialization of next-generation graphite materials. As a North American company, we are dedicated to securing a resilient, locally sourced supply of critical minerals - reducing dependence on foreign-controlled markets and driving the transition to a sustainable future.For more information on Focus Graphite Inc. please visit http://www.focusgraphite.com.LinkedIn: https://www.linkedin.com/company/focus-graphite/ X: https://x.com/focusgraphiteInvestors Contact: Dean Hanisch CEO, Focus Graphite Inc. dhanisch@focusgraphite.com +1 (613) 612-6060Jason LatkowcerVP Corporate Developmentjlatkowcer@focusgraphite.comCautionary Note Regarding Forward-Looking StatementsCertain statements contained in this press release constitute forward-looking information. These statements relate to future events or future performance. The use of any of the words "could," "intend," "expect," "believe," "will," "projected," "estimated," and similar expressions, as well as statements relating to matters that are not historical facts, are intended to identify forward-looking information and are based on the Company's current beliefs or assumptions as to the outcome and timing of such future events.In particular, this press release contains forward-looking information regarding, among other things, the anticipated performance and downstream applicability of ultra-high-purity graphite derived from the Lac Knife project; the potential for 5N+ purification results and nuclear-grade Equivalent Boron Concentration ("EBC") values to be replicated at larger scale; the implications of testwork conducted under Natural Resources Canada's Global Partnerships Initiative ("GPI") and the expected outcomes of related engineering, scale-up, and validation programs; the ability of Lac Knife graphite to meet nuclear, graphene, defense, electromagnetic shielding, thermal management, semiconductor, and other advanced material specifications; the potential commercial pathways associated with supplying high-purity natural graphite as an alternative to synthetic graphite; and the Company's strategy to position itself within North American supply chains for clean energy, advanced manufacturing, aerospace, and critical infrastructure markets.Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results, performance, or achievements to differ materially from those expressed or implied by such statements. These risks and uncertainties include, but are not limited to, risks related to market conditions, regulatory approvals, changes in economic conditions, the ability to raise sufficient funds on acceptable terms or at all, operational risks associated with mineral exploration and development, and other risks detailed from time to time in the Company's public disclosure documents available under its profile on SEDAR+.The forward-looking information contained in this release is made as of the date hereof, and the Company is not obligated to update or revise any forward-looking information, whether as a result of new information, future events, or otherwise, except as required by applicable securities laws. Because of the risks, uncertainties, and assumptions contained herein, investors should not place undue reliance on forward-looking information.Neither TSX Venture Exchange nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/277711 Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Town Health & Pfizer Join Forces to Promote Territory-wide Respiratory Health Education

EQS via SeaPRwire.com / 11/12/2025 / 17:30 UTC+8 Town Health Charity Foundation Donates 20-valent Pneumococcal Conjugate Vaccines TWGHs Collaborates on Community Vaccination (Hong Kong, 11 December, 2025) Town Health International Medical Group Limited (“Town Health”) has partnered with Pfizer Corporation Hong Kong Limited (“Pfizer”) to promote territory-wide respiratory health education. Town Health announced today that, through the Town Health Charity Foundation, it is donating a batch of 20‑valent pneumococcal conjugate vaccine (“PCV20”) (Manufacturer: Pfizer) to Tung Wah Group of Hospitals (“TWGHs”) to support vulnerable groups, strengthening medical–social collaboration to enhance community health protection. Town Health and Pfizer are actively responding to the Primary Healthcare Blueprint of the Hong Kong Health Bureau and are launching a territory‑wide respiratory health education initiative jointly to promote a shift in the public’s mindset from “treatment-based” to “prevention-oriented”. Meanwhile, Town Health will leverage its extensive network of medical centres across Hong Kong to facilitate the public access to protection through PCV20. As a key community partner, TWGHs will oversee proper allocation of the PCV20 donated by the Town Health Charity Foundation and identify suitable beneficiaries across its service units for vaccination. Town Health, Pfizer and TWGHs will continue to work closely together to uphold Town Health Charity Foundation’s vision of “Guided by Love, Advancing Health for All”—to reduce the disease burden among underserved groups and enhance the overall health of the community. Photo caption: Mr. Karson Choi Ka Tsan, GBS, JP, Chairman and CEO of Town Health (center), Dr. Alan Koo Chung Wai, Vice Medical Director of Town Health (third right), Mr. Huang Yu, Executive Director of Town Health (second right), Ms. Zhang Xiaoxue, Executive Director of Town Health (first right), Mr. Thomas Chan Chun Hong, COO of Town Health (first left), Dr. Wong Kam Cheung, Specialist in Respiratory Medicine (third left), Mr. Nicholas Chan, Commercial Lead of Pfizer Hong Kong and Macau (fourth right), Mr. Albert Kwong, Strategic Healthcare Partner, Cross Business Units of Pfizer Hong Kong and Macau (second left), and Dr. Chan Lee, Head of TWGHs K B Tam & W K Li Medical Centre (North Point) (fourth left) attended the vaccine donation ceremony together to jointly promote preventive health for all and build a safer community. ~ Cont. ~ Mr. Karson Choi Ka Tsan, GBS, JP, Chairman and CEO of Town Health, said that pneumococcal infections pose a significant public health threat in Hong Kong, particularly to the elderly and vulnerable groups, making public education on respiratory health an urgent priority. To this end, Town Health has introduced the PCV20, allowing the public to obtain broad protection against 20 Streptococcus pneumoniae serotypes with just a single dose. He added that through Town Health Charity Foundation’s donation of vaccines to TWGHs, Town Health is taking concrete action to support vulnerable groups through medical–social collaboration. Mr. Nicholas Chan, Commercial Lead of Pfizer Hong Kong and Macau, shared the view and emphasised that pneumococcal disease places a significant healthcare burden for Hong Kong society and believes that comprehensive Streptococcus pneumoniae serotype protection is essential. He hopes that this collaboration will enhance public understanding of pneumococcal disease. Dr. Chan Lee, Head of TWGHs K B Tam & W K Li Medical Centre (North Point), expressed gratitude to Town Health and Pfizer for their commitment to community health and TWGHs is honoured to serve as a community partner and is committed to the proper utilisation of the vaccines donated by the Town Health Charity Foundation to effectively support vulnerable groups in need. Dr. Alan Koo Chung Wai, Vice Medical Director of Town Health, reminded the public not to underestimate the threat of pneumonia. Dr. Koo noted that, according to the latest statistics from the Department of Health, pneumonia is the second leading cause of death in Hong Kong. In 2024, pneumonia caused more than 11,000 deaths, second only to cancer and surpassing heart disease and cerebrovascular disease¹. Streptococcus pneumoniae is a common cause of pneumonia, and over 100 serotypes have been identified². Vaccination is one of the most effective means of preventing pneumococcal disease. Dr. Wong Kam Cheung, Specialist in Respiratory Medicine, explained that pneumococci spreads through droplets or contact and has a short incubation period of around one to three days³. Early symptoms of pneumococcal pneumonia such as fever and cough often resemble influenza, leading to misdiagnosis. Co‑infection with influenza may also occur, increasing complexity in diagnostic and treatment. While pneumococci may cause milder illnesses such as otitis media or sinusitis, in high‑risk individuals it can lead to severe diseases such as invasive pneumonia, bacteraemia, sepsis, and meningitis3,4,5, with rapid deterioration that may be life‑threatening. Vaccination remains the most effective preventive measure which can significantly reduce the risk of invasive infections and severe outcomes3,4,5, and studies also show that it may lower the risk of heart attacks among high‑risk individuals⁶. Although antibiotics are the mainstream of treatment, antibiotic resistance made therapy increasing difficult³. Dr. Wong reiterated that “prevention takes precedence over treatment”, particularly in addressing pneumococcal infections. For details on the indications and usage of pneumococcal conjugate vaccines, please consult your doctor. ~ Ends ~ About Town Health: Build Healthier Life and A Better Tomorrow Town Health International Medical Group Limited (Stock Code: 3886.HK) is one of the largest listed healthcare groups with the longest history in Hong Kong and it is one of the few local comprehensive medical institutions that provides healthcare services in both Hong Kong and the Mainland China. The Group boasts high-quality medical resources and a strong professional medical team. Its business segments include: (i) The provision of medical services in Hong Kong; (ii) The provision of medical network management business in Hong Kong; (iii) The provision of hospital management and health management businesses in the Mainland China; and (iv) The provision of aesthetic medical and beauty and wellness services in Hong Kong and the Mainland China. The Group is committed to become an international first-class medical group rooted in Hong Kong, covering Greater Bay Area and serving the whole country, and is dedicated to build healthier life and a better tomorrow. To learn more, please visit us on https://thmd.townhealth.com and follow us on https://www.facebook.com/TownHealthMedicalHK. About Town Health Charity Foundation: Concerns The Needs of Society Town Health takes “Corporate Social Responsibility” as an important developing direction with the aim of being responsible for the stakeholders, the community and the environment. These years, Town Health has supported the local charity organisations in various ways and has delivered various support services to the vulnerable community. Up to now, the Group is being acknowledged by HKCSS as “Caring Company” in consecutive years. On 8 October 2015, the Group sets up Town Health Charity Foundation and takes “Supporting Underprivileged” and “Promoting Healthy Lifestyle” as main direction. The Foundation hopes to provide funding for local NGOs and allow them to deliver social services to the needy. About Tung Wah Group of Hospitals: Tung Wah Group of Hospitals, founded in 1870, is the oldest and well-established charitable organisation in Hong Kong. The Group is providing medical, educational, community and traditional services with the mission of “healing the sick and relieving the distressed, caring for the elderly and rehabilitating the disabled, promoting education and nurturing the youngsters, and raising the infant and guiding the youth”. Regarding the medical and health services, Tung Wah Group manages 5 hospitals (Tung Wah Hospital, Kwong Wah Hospital, Tung Wah Eastern Hospital, TWGHs Wong Tai Sin Hospital and TWGHs Fung Yiu King Hospital.), 42 Chinese and Western medicine services units and 1 community pharmacy, which provide Chinese and western medicine services, screening, computed tomography, dental and elderly health services. Tung Wah Group endeavors to develop its medical and health services to meet with the needs of the community. It has also established various patient assistance programmes to provide subsidy to needy people to facilitate them receiving medical services, with the aim to promote public health. For further information of Tung Wah Group, please visit www.tungwah.org.hk. About Pfizer: Breakthroughs That Change Patients’ LivesAt Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world’s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For 175 years, we have worked to make a difference for all who rely on us. To learn more, please visit us on www.pfizer.com.hk and like us on YouTube at www.youtube.com/c/pfizerhongkong. About 20-valent pneumococcal conjugate vaccine (PCV20): PCV20 is Pfizer’s next-generation pneumococcal conjugate vaccine that includes capsular polysaccharide conjugates for the 13 serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) already included in Pneumococcal 13-valent Conjugate Vaccine [Diphtheria CRM197 Protein]. The vaccine also contains capsular polysaccharide conjugates for seven additional serotypes (8, 10A, 11A, 12F, 15B, 22F and 33F) that cause invasive pneumococcal disease, and have been associated with high case-fatality rates, antibiotic resistance, and/or meningitis. PCV20 contains the broadest serotype coverage of any available pneumococcal conjugate vaccine and helps combat against the 20 Streptococcus pneumoniae serotypes in the vaccine. High-risk groups for pneumococcal infections include3,4,5: Children Elderly Others: History of invasive pneumococcal disease, cerebrospinal fluid leakage or cochlear implant; Chronic cardiovascular (except hypertension without complication), lung, liver or kidney diseases; Metabolic diseases including diabetes mellitus or obesity (Body Mass Index 30 or above); Immunocompromised states related to weakened immune system due to conditions such as asplenia, HIV/AIDS or cancer/steroid treatment; and Chronic neurological conditions that can compromise respiratory functions, the handling of respiratory secretions, increase the risk for aspiration or those who lack the ability to take care of themselves. Centre for Health Protection. Number of Registered Deaths by Leading Cause of Death, 2001-2024. https://www.chp.gov.hk/tc/statistics/data/10/27/380.html Bertran, Marta et al (2024, March 27). Invasive pneumococcal disease 3 years after introduction of a reduced 1+1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study, The Lancet Infectious Diseases, Volume 24, Issue 5, 546 – 556. Centre for Health Protection. Pneumococcal Infection. https://www.chp.gov.hk/en/healthtopics/content/24/10584.html U.S. Centers for Disease Control and Prevention. Pneumococcal Disease. https://www.cdc.gov/pneumococcal/index.html Centre for Health Protection. Pneumococcal Vaccination. https://www.chp.gov.hk/en/features/108124.html Bettina Heidecker, Peter Libby, Vassilios S Vassiliou, François Roubille, Orly Vardeny, Christian Hassager, Michael A Gatzoulis, Mamas A Mamas, Leslie T Cooper, Felix Schoenrath, Marco Metra, Offer Amir, Scott D Solomon, Ulf Landmesser, Thomas F Lüscher. Vaccination as a new form of cardiovascular prevention: a European Society of Cardiology clinical consensus statement: With the contribution of the European Association of Preventive Cardiology (EAPC), the Association for Acute Cardio Vascular Care (ACVC), and the Heart Failure Association (HFA) of the ESC, European Heart Journal, Volume 46, Issue 36, 21 September 2025, Pages 3518–3531. https://doi.org/10.1093/eurheartj/ehaf384 11/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More
Nasdaq Verafin Joins Global Anti-Scam Alliance ACN Newswire

Nasdaq Verafin Joins Global Anti-Scam Alliance

THE HAGUE, NETHERLANDS, Dec 10, 2025 - (ACN Newswire via SeaPRwire.com) - The Global Anti-Scam Alliance (GASA) is pleased to announce that Nasdaq Verafin has joined GASA as a Foundation Member, strengthening the global effort to combat scams, financial crime, and digital fraud. As fraud tactics continue to evolve across borders and digital channels, cross-sector collaboration has become essential to protecting consumers and building safer financial ecosystems.Nasdaq Verafin's participation marks a meaningful step forward in the shared mission to advance trust, transparency, and resilience across the globe. In addition to joining the global effort, Nasdaq Verafin will join both the Brazil and Mexico chapters of GASA to partner with stakeholders across the financial ecosystem in Latin America, bolstering regional initiatives to combat financial crime."Criminals are innovating at an unprecedented rate, taking advantage of information siloes and the shortcomings of legacy technology to avoid detection. We are at an inflection point in the fight against financial crime, one that requires the entire ecosystem to come together, leveraging the power of collective intelligence to strengthen our defenses and better protect consumers around the globe. We look forward to partnering closely with the Global Anti-Scam Alliance to share innovative solutions, intelligence, and global expertise to the unique challenges financial institutions in Brazil and Mexico face," said Mauriceo Castanheiro, Head of International Payments Fraud at Nasdaq Verafin.Nasdaq Verafin is a global leader in financial crime management technology solutions, trusted by more than 2,700 financial institutions around the globe. The company's innovative approach combines consortium data, AI, and machine learning to deter, detect, and prevent criminal activity. Nasdaq Verafin's consortium approach uncovers hidden risks across the financial system, leveraging data and insights from across 800 million counterparties to improve fraud detection and prevention while reducing false positives."Having Nasdaq Verafin join the Global Anti-Scam Alliance as a Foundation Member is a milestone for our organization and for the global fight against scams. Their deep expertise in leveraging technology to more efficiently and effectively detect criminal activity brings a new level of insight and influence to our mission. With Nasdaq Verafin's partnership, and their representatives joining the boards of our Brazil and Mexico Chapters, we are strengthening our ability to connect global knowledge with local action. Together, we can help shape stronger policies, accelerate industry collaboration, and build the foundations of a scam free future." said Jorij Abraham, Managing Director of GASA."The addition of Nasdaq Verafin as a Foundation Member is not only a milestone for the Brazil Chapter, it is a strong endorsement of the relevance of our market and the seriousness of the work we have been building from day one. We are starting our journey already alongside a globally recognized institution known for excellence, innovation, and a deep commitment to integrity. This partnership strengthens our ability to translate global expertise into local impact and accelerates our mission to raise the standard of collaboration in the fight against scams and financial crime in Brazil." said Renata Salvini, Chapter Director for Brazil."With 76 percent of Mexican adults victimized by scams and 139 billion pesos lost annually, according to the 2025 State of Scams in Mexico Report, 2026 will be devastating. AI democratized productivity but industrialized fraud, this isn't a prediction, it's a countdown. Combating this epidemic requires integrated defenses where early detection triggers coordinated action across digital platforms, telecommunications, finance, and authorities. Nasdaq Verafin's addition to GASA Mexico bridges the gap between technology and coordination. Without systemic collaboration, our economic system remains vulnerable. This strengthens our multistakeholder commitment to essential stability", added Sissi de la Peña, Chapter Director for Mexico.Through this partnership, Nasdaq Verafin executives will join the Chapter Advisory Boards of GASA Mexico and Brazil. As a Foundation Member, Nasdaq Verafin will collaborate with GASA and its members, bringing insights from more than two decades of stopping financial crime to develop innovative new strategies that protect consumers from fraud and scams.To learn more about Nasdaq Verafin's approach to financial crime detection and prevention, visit www.verafin.com.About the Global Anti-Scam Alliance (GASA)The Global Anti-Scam Alliance is a non profit organization whose mission is to protect consumers worldwide from scams. GASA brings together policymakers, law enforcement agencies, consumer authorities, NGOs, the financial sector, telecom operators, internet platforms, service providers, and cybersecurity organizations to share insights, uncover emerging scams, and promote coordinated action against fraud. Learn more at https://www.gasa.org.About Nasdaq VerafinNasdaq Verafin provides Financial Crime Management Technology solutions for Fraud Detection and Management, AML/CFT Compliance and Management, High Risk Customer Management, Sanctions Screening and Management, and Information Sharing. More than 2,700 financial institutions, representing 11 trillion dollars in collective assets, use Nasdaq Verafin to prevent fraud and strengthen AML/CFT efforts. Visit www.verafin.com to learn more.Cautionary Note Regarding Forward-Looking Statements:Information set forth in this release contains forward-looking statements that involve a number of risks and uncertainties. Nasdaq cautions readers that any forward-looking information is not a guarantee of future performance and that actual results could differ materially from those contained in the forward-looking information. Forward-looking statements can be identified by words such as "will", "may" and other words and terms of similar meaning. Such forward-looking statements include, but are not limited to, statements related to future actions and expected results. Forward-looking statements involve a number of risks, uncertainties or other factors beyond Nasdaq's control. These risks and uncertainties are detailed in Nasdaq's filings with the U.S. Securities and Exchange Commission, including its annual reports on Form 10-K and quarterly reports on Form 10-Q which are available on Nasdaq's investor relations website at http://ir.nasdaq.com and the SEC's website at www.sec.gov. Nasdaq undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.© 2005 Nasdaq, Inc. The Nasdaq logo and the Nasdaq ‘ribbon' logo are the registered and unregistered trademarks, or service marks, of Nasdaq, Inc. in the U.S. and other countries. All rights reserved. This communication and the content found by following any link herein are being provided to you by Nasdaq, Inc. and/or certain of its subsidiaries (collectively, "Nasdaq"), for informational purposes only. Nasdaq makes no representation or warranty with respect to this communication or such content and expressly disclaims any implied warranty under law. At the time of publication, the information herein was believed to be accurate, however, such information is subject to change without notice. Nothing herein shall constitute a recommendation, solicitation, invitation, inducement, promotion, or offer for the purchase or sale of any investment product, nor shall this material be construed in any way as investment, legal, or tax advice, or as a recommendation, reference, or endorsement by Nasdaq.GASA Media ContactMetje van der MeerMarketing Directormetje.vandermeer@gasa.org+31 6 48456282Nasdaq Contact:Nick EghtessadCorporate Communicationsnick.eghtessad@nasdaq.com+1 929 996-8894SOURCE: Global Anti-Scam Alliance Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards ACN Newswire

Dr. Teck Lim Chia, Chairman and CEO of CBL International, Honored at the Prestigious Directors of the Year Awards

KUALA LUMPUR, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – CBL International Limited (NASDAQ: BANL) (the “Company” or “CBL”), the listing vehicle of the Banle Group (“Banle” or “the Group”) is honored to announce that Dr. Teck Lim Chia, Chairman and Chief Executive Officer of CBL International Limited, has been selected as an Awardee in the Directors of the Year Awards – Listed Companies Executive Directors category, presented by the Hong Kong Institute of Directors (HKIoD).This esteemed accolade follows a comprehensive evaluation by an independent panel of judges comprising senior business leaders, governance experts, and institutional investors. The award recognizes Dr. Chia’s outstanding contributions to corporate governance, exemplary board leadership, and his proven track record in driving sustainable value creation for shareholders and stakeholders.The HKIoD Directors of the Year Awards are among Asia’s most respected honors in corporate governance. Awardees are chosen based on demonstrated excellence in strategic oversight, ethical leadership, transparency, and long-term sustainable performance—all hallmarks of Dr. Chia’s tenure at CBL International. As Chairman and CEO, Dr. Chia has led the Group through a period of transformative growth while embedding governance excellence into the company’s core. Under his stewardship, CBL has strengthened its investor relations framework, enhanced ESG disclosures, deepened stakeholder engagement, and maintained rigorous compliance with international standards throughout its expansion across Asia Pacific, Europe, Central America and Africa.In accepting the award, Dr. Teck Lim Chia said: “I am deeply humbled and grateful to receive this prestigious recognition from the Hong Kong Institute of Directors. This honor belongs not to me alone, but to our entire board, management team, and employees who share a relentless commitment to integrity, innovation, and responsible growth. At CBL, we believe governance is not a box to check — it is the compass that guides every decision. I will continue to lead with purpose, accountability, and vision, always placing the long-term interests of our stakeholders first.”The Board of CBL International expressed its pride in Dr. Chia’s achievement: “Dr. Chia’s leadership has been instrumental in shaping CBL into a globally recognized, governance-forward enterprise. His ability to balance strategic ambition with disciplined oversight exemplifies what modern corporate leadership should be. We congratulate him on this well-deserved honor.”Photo caption: Dr. Teck Lim Chia (right), Chairman and CEO of CBL International Limited, honored at the Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).Photo caption: The trophy for Directors of the Year Awards – Listed Companies Executive Directors category by the Hong Kong Institute of Directors (HKIoD).About the Banle GroupCBL International Limited (Nasdaq: BANL) is the listing vehicle of Banle Group, a reputable marine fuel logistics company based in the Asia Pacific region that was established in 2015. We are committed to providing customers with a one-stop solution for vessel refueling, which is referred to as bunkering facilitator in the bunkering industry. We facilitate vessel refueling mainly through local physical suppliers in 65 major ports covering Belgium, China, Hong Kong, India, Japan, Korea, Malaysia, Mauritius, Panama, the Philippines, Singapore, Taiwan, Thailand, Turkey and Vietnam. The Group actively promotes the use of sustainable fuels and has been awarded the ISCC EU and ISCC Plus certifications.For more information about our Company, please visit our website at: https://www.banle-intl.com. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

Cloudbreak Pharma Soars 80%+ on Multiple Catalysts, Driving Value Re-Rating

HONG KONG, December 11, 2025 - (ACN Newswire via SeaPRwire.com) – Since 2025, driven by both policy tailwinds and fundamental strengths, the innovative drug sector in the Hong Kong stock market has experienced a valuation recovery. Although it experienced some correction in the second half due to external environmental factors, its overarching growth logic remains intact. Institutional analysis indicates that innovative drugs continue to represent the clearest industry trend within the pharmaceutical sector, with promising development prospects ahead.Among the players, Cloudbreak Pharma (2592.HK), a biotech company focused on ophthalmology, has recently demonstrated strong stock performance. As of December 9, its share price closed at HK$8.24, having accumulated a gain of over 80% in approximately two weeks, and making it a standout "star stock" in the capital markets. This impressive performance is not coincidental but rather the inevitable result of multiple positive catalysts converging, including breakthroughs in its core product pipeline, enhancements to its global intellectual property (IP) layout, and an upgrade of its core management team.Securing Another Victory in Patent Layout, Accelerating Commercialization of Core ProductOn November 27, Cloudbreak Pharma's wholly-owned subsidiary, ADS Therapeutics LLC, successfully secured two core patents in Japan and Europe. Both patents relate to ophthalmic topical compositions and their uses for the core product CBT-009, laying a legal foundation for its global commercialization.As a novel atropine ophthalmic formulation for treating myopia in children and adolescents aged 5 to 19, CBT-009, with its unique non-aqueous formulation design, demonstrates potential advantages over traditional aqueous formulations in terms of drug stability, safety, and patient tolerability, positioning it as a potential best-in-class product. Currently, the product's development is progressing steadily. It received U.S. FDA approval to initiate Phase 3 clinical trial in September 2024. Juvenile animal toxicity studies in China commenced in February 2025, and preparations for Phase 3 clinical trial are actively underway.The grant of these patents in Japan and Europe not only strengthens the global IP portfolio for CBT-009, but will also accelerate its commercialization process. Leveraging patent protection, the Company has the potential to establish partnerships with global pharmaceutical giants to advance the product's production and distribution in key markets like Japan and Europe, accelerating global market penetration. Given the severity of the global adolescent myopia issue, CBT-009 is expected to become a core engine for the Company's future performance growth.Pipeline Progress Across Multiple Fronts; CBT-004 Advances Towards Phase 3Beyond CBT-009, another promising drug candidate from Cloudbreak Pharma, CBT-004, has also reached a significant milestone. As a potential first-in-class drug for vascularized pinguecula, CBT-004 uses Multi-Kinase Inhibitor targeting Vascular Endothelial Growth Factor Receptor (VEGFR) and Platelet-Derived Growth Factor Receptor (PDGFR). According to the Company's latest disclosures, CBT-004 yielded positive results in a Phase 2 clinical trial evaluating its safety and efficacy in treating pinguecula. The Company has begun advancing its Phase 3 clinical development and is scheduled to meet with the United States Food and Drug Administration (the “FDA”) on December 10 (Pacific Standard Time, PST) at an End-of-Phase 2 meeting to establish a regulatory pathway for potential approval.It is understood that there are currently no approved drugs globally specifically for treating vascularized pinguecula. Existing treatment options mostly offer temporary symptomatic relief, leaving significant unmet clinical needs. Should CBT-004 successfully complete development and gain approval, it would become the first targeted therapy, rapidly capturing market share with its unique efficacy advantages. This would create a new revenue stream for the Company while further solidifying its leading position in the field of ophthalmic innovative drugs.Strengthened Executive Team Elevates Commercialization CapabilitiesThe success of innovative drugs relies not only on R&D prowess but also on robust commercialization capabilities to realize their value. On December 1, 2025, Cloudbreak Pharma announced the official appointment of Mr. Michael Rowe as its new Chief Business Officer (CBO), injecting key momentum into the Company's global commercial strategy.Public information shows that Mr. Michael Rowe possesses substantial hands-on commercialization experience across senior management, marketing, sales management, and clinical operations. He is particularly skilled in driving organizational efficiency and achieving breakthroughs in innovative business areas. His industry resources and operational capabilities are expected to bring comprehensive enhancements to the Company.This executive appointment coincides with Cloudbreak Pharma’s core products entering a critical preparatory phase for commercialization. Mr. Michael Rowe's joining will strengthen the Company's business development capabilities in European and American markets, accelerating the construction of its global commercial footprint. Currently, through collaborations with companies such as Grand Pharmaceutical Group and Santen, Cloudbreak Pharma has established a commercialization foundation in Greater China and the Asia-Pacific region (excluding China). With the new CBO onboard, the Company is poised to further expand its global partnership network, optimize commercialization strategies, and provide robust support for the market entry of its multiple core products.With Sustained High Industry Growth, Valuation Re-rating Potential RemainsIn recent years, the global incidence of ophthalmic diseases has continued to rise. Conditions like pterygium and adolescent myopia affect hundreds of millions of patients, while the supply of innovative drugs in related treatment areas remains severely inadequate, indicating a vast unmet market need. Concurrently, governments worldwide are increasing support for pharmaceutical innovation, providing a favorable policy environment for high-quality innovative drug companies. Within the Hong Kong stock market, the innovative drug sector is experiencing a favorable trend of valuation re-rating. Companies with solid R&D pipelines, clear commercialization pathways, and core competitiveness are seeing gradually rising valuation expectations.As an innovative drug company dedicated to ophthalmology, Cloudbreak Pharma has built a rich pipeline covering 8 drug candidates targeting major diseases in both the anterior and posterior segments of the eye, forming a diversified product matrix. With steady progress in R&D and an increasingly refined global commercialization strategy, the Company already exhibits scarce growth attributes. The recent short-term surge in its stock price, catalyzed by multiple positive factors, is merely the beginning of value release. As these favorable initiatives are further implemented and pipeline value continues to be realized, Cloudbreak Pharma is poised to achieve dual enhancement in both performance and valuation. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline ACN Newswire

TIS Helps Treasury Teams Navigate the Ongoing ISO 20022 Transition After the 2025 Banking Deadline

BERLIN, Germany, Dec 10, 2025 - (ACN Newswire via SeaPRwire.com) - Treasury Intelligence Solutions (TIS), a leading cloud-based platform for payments and cash management, is future-proofing organizations with specialized translation services in the wake of the recent November 2025 ISO 20022 deadline. A major turning point for the financial industry, SWIFT now requires banks to move their cross-border payment messages to ISO 20022. As a result, treasury teams are already seeing differences in how their banks send and receive payment information. Adapting to these changes will require a strategic approach to modernizing systems and processes.ISO 20022 replaces a patchwork of older standards with a single approach to structuring payment data. The new universal standard is designed to reduce confusion across markets, improve data quality, and support the level of transparency that regulators around the globe now expect.Moving to ISO 20022 payments takes time and strategic vision, especially when legacy systems, ERP, and payment systems were not built with structured data in mind. Updating those requires planning and coordination across several internal teams."ISO 20022 is a major industry shift, but it shouldn't disrupt the way companies operate day-to-day," said Wouter De Bie, Chief Technology Officer at TIS. "Our priority is making this transition seamless. By leveraging our platform's ability to translate payment files into bank-specific formats and automatically populate ISO-required fields, we give treasury teams the flexibility to adapt at their own pace. This approach ensures stability, reduces risk, and empowers organizations to meet new standards without costly system overhauls or last-minute fixes."The TIS platform leverages more than 140,000 bank-specific profiles to provide comprehensive coverage of ISO bank formats. In addition, an innovative AI-powered solution addresses ISO-specific requirements such as structured address information for corporate beneficiaries. Companies that begin now to update their data and payment workflows will be better prepared for the larger changes still ahead. Those that don't may face frustrating problems like message truncation, rejected payments, and slower processing times as unstructured formats are phased out."We're already seeing the benefits of a proactive approach to ISO 20022," said Jon Paquette, Chief of Strategy at TIS. "Organizations using our platform have implemented early bank-driven changes without payment failures or costly rework and are also leveraging our statement format conversion capabilities to avoid disruptions in reconciliation and cash applications as banks sunset MT formats and introduce CAMT. This proves that with the right tools, companies can prepare for full ISO adoption on their own timelines - maintaining stability while meeting evolving standards."About TISTIS helps CFOs, Treasurers, and Finance teams transform their global cash flow, liquidity, and payment functions. Since 2010, our award-winning cloud platform and best-in-class service model have empowered the entire office of the CFO to collaborate more effectively and attain maximum efficiency, automation, and control. TIS enables users to achieve superior performance in key areas surrounding cash forecasting, working capital, outbound payments, financial messaging, fraud prevention, payment compliance, and more.To learn how TIS can support your ISO 20022 transition, contact us today.CONTACT:Blair Romain+496227698240blair.romain@tispayments.comSOURCE: Treasury Intelligence Solutions Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More

ActusRayPartners, a Quantitative Hedge Fund Manager, Secures Double Victory at the HFM European Performance Awards 2025

EQS via SeaPRwire.com / 10/12/2025 / 16:39 UTC+8 On 25 November 2025, ActusRayPartners won two prestigious awards at the HFM European Performance Awards 2025: 1) “European equity”, and 2) “Market-neutral”. These two accolades recognize the outstanding performance of the ActusRayPartners European Alpha Fund from 1 July 2022 to 30 June 2025. ActusRayPartners is a quantitatively oriented but ultimately discretionary hedge fund manager seeded and supported by Sun Hung Kai Capital Partners, the funds management platform of Sun Hung Kai & Co. Limited (“SHK & Co.”, SEHK: 86). Established in 2019, ActusRayPartners has achieved significant growth, with its assets under management (AUM) increasing over 100 times to surpass US$2 billion as of 30 November 2025. As equity markets advanced over the performance assessment period, it is a significant achievement that ActusRayPartners’ equity market-neutral work (which carries near-zero beta) was strong enough to win against both equity long-short (which often carries approximately 50% beta) and equity market-neutral peers in the same evaluation window. Since the “Market-neutral” category was introduced at the HFM European Performance Awards, no other hedge fund manager has won both best equity long-short and best equity market-neutral in the same year. Additionally, no other Asia-based manager has won either of these two categories for, at least, the past decade+. “As a Hong Kong-headquartered asset management company, we are proud that our European strategy has been consistently recognised since its inception in March 2021, including winning an award in each of the past three years. We believe these awards reflect the strength of our Discretionary Probabilistic Investing process and the dedication of our team,” said the Co-Founders of ActusRayPartners. Tony Edwards, Executive Director and Deputy CEO of SHK & Co., commented: “Congratulations to the ActusRayPartners team on their remarkable double win at the HFM Performance Awards! To win in both the Equity Market-Neutral and Equity Long-Short categories is a significant achievement and a testament to their expertise and disciplined strategy. As a long-term seeding partner, we take great pride in their tremendous growth since our collaboration began five years ago. At SHK & Co., we remain dedicated to support and empower specialist emerging asset managers across Asia, helping them thrive in dynamic markets. ActusRayPartners exemplifies this partnership and commitment.” The HFM European Performance Awards is highly regarded in the hedge fund industry, honouring excellence in various categories such as fund performance, operational capabilities, and service providers. Organized by HFM Global, a leading source of hedge fund intelligence, these awards have a long history of celebrating firms that demonstrate exceptional performance and innovation. – End – About ActusRayPartners ActusRayPartners is a Hong Kong-headquartered asset management company equally co-founded by Andrew Alexander, Raymond Chan, and Patrick Cheung in 2019. Several members of the team previously worked together in the Quantitative Hedge Funds division of Macquarie Group. Today, ActusRayPartners comprises 36 members across Hong Kong and Sydney, managing over US$2 billion (as of 30 November 2025) across Europe and Asia. ActusRayPartners employs a Discretionary Probabilistic Investing process which is a synthesis of: (1) a quantitative base, and (2) discretionary adjustments to address quantitative deficiencies. The quantitative base uses fundamental, sentiment, technical and alternative data, and employs advanced statistics, natural language processing, and artificial intelligence techniques. The discretionary work focuses on addressing challenges with purely systematic processes and is not fundamental, macro or flow driven. ActusRayPartners is licensed by the Hong Kong Securities and Futures Commission (Type 4 “Advising on Securities” and Type 9 “Asset Management” license) and is a Registered Investment Adviser with the U.S. Securities and Exchange Commission and has not yet made an application to be licensed in any other jurisdiction. About Sun Hung Kai & Co. and Sun Hung Kai Capital Partners Sun Hung Kai & Co. Limited (SEHK: 86) (“SHK & Co.” / the “Company”, together with its subsidiaries, the “Group”) is a leading Hong Kong-based financial institution recognised for its expertise in alternative investments and wealth management. Since 1969, the Company has built a diversified investment portfolio across public markets, credit and alternatives strategies including real estate and private equity, delivering long-term risk-adjusted returns. Leveraging on its deep-rooted Asian heritage, SHK & Co. supports and nurtures specialist emerging asset managers in the region, empowering them to excel. SHK & Co. also utilises its long-standing investment expertise and resources in providing tailored investment solutions to like-minded partners and ultra-high-net-worth investors through its Family Office Solutions. As at 30 June 2025, the Group held about HK$37.7 billion in total assets. For more information, please visit: www.shkco.com / follow SHK & Co. on LinkedIn. Founded in 2020, Sun Hung Kai Capital Partners Limited (“SHKCP”) is a Hong Kong SFC regulated subsidiary of SHK & Co., with Type 1, 4 and 9 licenses. For more information, please visit: www.shkcapital.com / follow SHKCP on LinkedIn. For media enquiries, please contact: Burson Sidney Leng +852 5443 4320 Caleb Leung +852 9190 1969 Joyce Zhan +852 9142 2528 Email: SHKCo@hkstrategies.com 10/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More

Beyond ONE’s Friendi Pay Reports Surge in Oman’s Digital Payments Only Five Months After Its Launch

EQS via SeaPRwire.com / 10/12/2025 / 15:59 UTC+8 Muscat, Oman - December 10, 2025 - (SeaPRwire) - Beyond ONE shares a surge in Oman's digital payments sector following the launch of its platform, Friendi Pay. The digital service, rolled out in May 2025, has spurred a 600% in digital payments and more than 800% growth in international remittances. Additionally, within this short timeframe, Friendi Pay has seen monthly transaction volumes expand from thousands to tens of thousands, with the value of domestic transfers climbing by over 360% to nearly one million Omani rials. The platform's onboarding rate has also improved by 55%, signaling a shift in how Omani residents and expatriates manage their finances both at home and abroad, and demonstrating the widespread appeal of trustworthy, transparent, and easy-to-use digital finance solutions. Human-Centric Design And Commitment To Trust Friendi Pay is anchored in the understanding that trust is the cornerstone of advancement in financial technology. Every transaction is safeguarded by comprehensive Know Your Customer (KYC) and Anti-Money Laundering (AML) protocols, with continuous collaboration alongside the Central Bank of Oman to ensure payments consistently meet the nation's highest security standards. "Families deserve clarity upfront and transparency at every stage. We show the full cost and let every user track their transaction step by step," Tawfiq Al Lawati, CEO of Friendi Pay Oman, mentions. Beyond security infrastructure, Friendi Pay delivers accessibility through design. The platform operates with WhatsApp-first support and a user interface available in five languages: Arabic, English, Hindi, Bengali, and Tagalog, enabling onboarding, inquiries, and assistance through real-time, multilingual communication channels. Rooted in the behavioral habits of over one million Friendi Mobile users, the platform integrates seamlessly with diverse lifestyles, meeting people "where they are" and addressing the everyday financial needs of local families and expatriates alike. From utility bill payments and in-store purchases to remittances and peer-to-peer transfers, Friendi Pay seamlessly integrates digital finance into daily life. Hani ELKukhun, CEO of Middle East at Beyond ONE, states, "We are not just simplifying transactions, we are humanizing finance for real lives and real communities." Responsible Innovation In A Rapidly Growing Market Amid forecasts that Oman's digital payments sector will exceed $20.8 billion by 2029, Friendi Pay sets the standard for responsible, compliance-oriented fintech development. Every new feature and payment corridor undergoes rigorous internal and regulatory scrutiny before launch. Transparent fee structures, real-time transaction visibility, and accessible support empower users to navigate a market that is becoming more competitive and consumer-centric by the day. The ripple effect is greater consumer literacy, informed comparisons between services, and accountability-driven competition. In doing so, Friendi Pay is disrupting the market while proving that profitability and principle can coexist in the same product. Available on both the Apple App Store and Google Play, Friendi Pay is open to all residents of Oman. Its journey in the fintech space has just begun, but the platform is committed to supporting real household needs, driving financial inclusion, and aligning the country's vision for a stronger digital financial economy. "As Oman moves toward Vision 2040 and a diversified digital economy, Friendi Pay will deliver ever more local payment solutions, open fresh remittance corridors, and set new standards for customer experience," mentions Al Lawati. "Progress happens when fintech listens to real people. That's how we ensure growth is responsible, sustainable, and empowering, at scale." About Beyond ONE Beyond ONE is a global digital services aggregator founded in 2021 and headquartered in Dubai, with a strong presence in Latin America and the Middle East. Their mission is to simplify people's lives by delivering the right services, at the right time, for the right reason, to the right people, all in one trusted place. Contact Details Brand: Beyond ONE Contact: Ahmed Ibrahim, Director of PR and Social Media Email: ahmed.ibrahim@beyond.one Website: https://beyond.one 10/12/2025 Dissemination of a Financial Press Release, transmitted by EQS News.The issuer is solely responsible for the content of this announcement.Media archive at www.todayir.com
More
‘M’ Mark Event – HKGX 2025 IBF World Championships ACN Newswire

‘M’ Mark Event – HKGX 2025 IBF World Championships

The HKGX 2025 IBF World Championships concluded with a grand finale at Queen Elizabeth Stadium on 5 December.HONG KONG, December 10, 2025 - (ACN Newswire via SeaPRwire.com) – The HKGX 2025 IBF World Championships concluded in a grand finale at Queen Elizabeth Stadium with France securing gold in Men’s Team of 5-players Event and USA claiming gold in Women’s Team of 5-players Event.Men’s and Women’s Team of 5-players Event Semi-Finals and Finals were conducted today in a best of three games Baker’s Format which five players each bowl alternate frame in one single game. In the Men’s Team of 5-players Event Finals, France captured gold medal by defeating Sweden (264-248, 257-228). The bronze medals were shared by Germany and Korea. The Women’s Team of 5-players final featured a rematch of the 2025 IBF World Cup Women’s Team Event Finals. USA attained Gold Medal beating Malaysia in three games (179-191, 200-159, 199-185). The bronze medals were shared by Japan and Korea.The All Events medals were awarded “based on the sum of the finishing position in each event. The winner was the athlete with the least number of points based on finishing position in each event.” For Men’s All Events, Sweden’s James Blomgren attained Gold Medal, Korea’s Ji Guen got Silver Medal and The Czech Republic’s Lukas Jelinek claimed Bronze Medal. For Women’s All Events, Finland’s Essi Pakarinen captured Gold Medal, USA’s Shannon Pluhowsky got Silver Medal and Singapore’s Shayna Ng claimed Bronze Medal. Overall federation champion medals were also awarded “based on the sum of finishing positions in each discipline.” For Men’s Division, Sweden attained Gold Medal, Denmark took Silver and Korea got Bronze. For Women’s Division, USA captured Gold Medal, Singapore got Silver and Malaysia achieved Bronze.Ms. Vivien Lau, SBS, JP, Chairman of the Hong Kong, China Tenpin Bowling Congress wrapped up the successful Championships with a heartfelt message. “Success of the Championships depends on how all the participants felt to them whether the Championships is successful or not. I will be happy if everyone felt the Championships is a success and they are happy to be here in Hong Kong. ” She thanked all the athletes and federations for taking part in the Championships. Without them, there would be no Championships.Hong Kong, China Tenpin Bowling Congress would like to extend its gratitude and appreciation to the Major Sports Events Committee; Title Sponsor, the Hong Kong Gold Exchange (HKGX); Official Community Partner, The Hong Kong Jockey Club; Platinum Sponsor, Asiaray Media Group Limited; all other sponsors including First Asia Merchants Bullion Limited, UPWAY Group, Golday Financial Group Limited, Tak Fung International (HK) Limited, New Territories General Chamber of Commerce and Auspicious Bullion Limited; Official Partners Shun Hing Electronic Trading Company Limited, Joinmax (H.K.) Limited and all supporting organizations.The next edition of the IBF World Championships will be held in Korea in 2027. Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
HKiNEDA Annual Conference Successfully Concludes ACN Newswire

HKiNEDA Annual Conference Successfully Concludes

HONG KONG, December 10, 2025 - (ACN Newswire via SeaPRwire.com) – The Hong Kong Independent Non-Executive Director Association (“HKiNEDA”) successfully held its Annual Conference last Saturday. This year's theme, “Opportunities and Challenges for INEDs in Dual Listing Wave, Digital Asset Era, and Web3 & AI-Driven Risks”, brought together representatives from Hong Kong's key financial regulators, alongside industry experts and corporate leaders from across the region. The event attracted nearly 300 senior executives. The Association presented the INED Honorary Life Achievement Award to Dr Rita Fan Hsu and Prof. Frederick Ma in recognition of their outstanding contributions to the profession and to corporate governance.In light of the Tai Po fire incident, the opening ceremony included a solemn tribute to commemorate the victims and honour the bravery of the firefighters. The conference was formally opened with a welcome address by Mr Rex Yeung, President of HKiNEDA.In his speech, Mr Yeung underscored the irreplaceable role of INEDs in strengthening corporate governance: “We need three-dimensional thinking — dual listings, digital assets and driven risks by Web3 and AI — with depth, clarity and transparency. This is exactly how we should approach governance: making strategies more understandable, decisions more traceable and outcomes more accountable. That's the shift we must embrace: moving from flat compliance to three-dimensional stewardship — for investors, regulators and all stakeholders we serve. As INEDs, we are not only the gatekeepers of enterprises but also the guardians of market transparency and investor trust.”Distinguished guests at the opening ceremony included Dr Kelvin Wong, Chairman of the Securities and Futures Commission; Dr David Sun, Chairman of the Accounting and Financial Reporting Council; and Dr Rocky Tung, Director, Head of Policy Research for the Financial Services Development Council.Organisers and officiating guests kick off the HKiNEDA Annual Conference 2025.From left to right:1. Mr Roy Lo, Co-Chairman, Organising Committee of Annual Conference 20252. Mr Zhou Yi, Executive Vice President, Lingbao Gold Group Company Limited3. Dr Kelvin Wong, Chairman of the Securities and Futures Commission4. Mr Rex Yeung, President, HKiNEDA5. Dr David Sun, Chairman of the Accounting and Financial Reporting Council6. Dr Rocky Tung, Director, Head of Policy Research, Financial Services Development Council7. Datuk Shireen Muhiudeen, Founder, Corston-Smith Asset Management SDN BHD & Former Chairman, Bursa Malaysia8. Prof. Terence Chan, Co-Chairman, Organising Committee of Annual Conference 2025In response to recent trends in technological innovation and the evolution of financial models, the conference featured keynote addresses and panel discussions on three major topics: the strategic complexity of dual listings (A+H), the rise of digital assets, and the convergence of Web3 and artificial intelligence. Senior directors and professionals shared their insights, fostering lively exchange and enhancing awareness of emerging trends while strengthening oversight capabilities.Prominent speakers included (in order of appearance):- Mr Lucas Chen, Executive Director, Lingbao Gold Industrial Investment Company Limited- Datuk Shireen Muhiudeen, Founder, Corston-Smith Asset Management SDN BHD & Former Chairman, Bursa Malaysia- Mr Xie Jun, CEO, Leading Holding- Mr Vincent Pang, Managing Partner, AVISTA Group- Ms Diamantina Leong, Partner, Capital Market Services, PricewaterhouseCoopers- Mr Robert Lui, Southern Region Offering Services Leader of Capital Market Services Group and Hong Kong Digital Asset Leader, Deloitte China- Mr Simon Shum, Partner, Financial Services, Asset Management, HKSAR, KPMG China- Ms Bobo Lee, Manager, Blockchain & Digital Asset, Hong Kong Cyberport Management Company Limited- Mr Sangmin Park, Managing Director, DX Division, BEATOZ Inc.- Ms Michelle Cheng, Managing Director, HashKey Exchange- Mr Andrew Lee, Partner, Greater China Markets & Hong Kong EY Wavespace (Innovation) Leader- Mr Kenneth Lam, Partner, Grant Thornton Advisory Services Limited- Mr Andy Chow, Head of Customer Solution Architects, Google Cloud Hong KongThe conference concluded with the presentation of the Association's highest honour, the INED Honorary Life Achievement Award, to Dr Rita Fan Hsu (left in the photo below) and Prof. Frederick Ma (right in the photo below). Their outstanding achievements have set a benchmark for Independent Non-Executive Directors and have had a lasting impact on the advancement of corporate governance standards.About The Hong Kong Independent Non-Executive Director AssociationThe Hong Kong Independent Non-Executive Director Association (HKiNEDA), incorporated in Hong Kong by Companies Ordinance, is a non-profit association mainly representing INEDs of Greater China. Based in Hong Kong, the association connects INEDs of Mainland China, Hong Kong and Taiwan, to make dedicated contributions in the Greater China's enormous financial and capital market.HKiNEDA aims at enhancing professional development of INEDs, promoting healthy and outstanding corporate governance of listed companies, and sustainable development of the capital market in Greater China. To achieve the mission, the Association commits to helping INEDs to understand their duties in listed companies, encouraging them to realize their values, supporting INEDs to oversee companies and fulfill their responsibilities with independence, integrity and impartiality.For more information about HKiNEDA, please visit: http://www.hkineda.com/Media EnquiriesStrategic Public Relations GroupBrenda ChanTel: +852 2114 4396Email: brenda.chan@sprg.com.hkKaren NgTel: +852 2114 4978Email: karen.ng@sprg.com.hk Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More
Redefining Global Legal Services with Digital Intelligence China Entercom Empowers Yingke Law Firm to Win 2025 IDC China Future Enterprise Awards ACN Newswire

Redefining Global Legal Services with Digital Intelligence China Entercom Empowers Yingke Law Firm to Win 2025 IDC China Future Enterprise Awards

HONG KONG, December 10, 2025 - (ACN Newswire via SeaPRwire.com) – CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883) is pleased to announce that the ICT-empowered partner of its subsidiary, China Enterprise ICT Solutions Limited (“China Entercom”), Yingke Law Firm (“Yingke”), has earned industry recognition at the IDC China CIO Summit 2025 and IDC Future Enterprise Awards Digital Ceremony, where its pioneering benchmark project, “YingFaBao AI Legal Space Station” received the 2025 IDC China Future Enterprise Awards of Excellence - Future Enterprise of the Year. Dedicated to recognizing future enterprises who embrace the digital-first era, this accolade represents a milestone in the partnership between China Entercom and Yingke, and also serves as a testament to China Entercom’s role in fostering a digital and intelligent ecosystem to realize digital intelligence and globalization for businesses across industries. Ms. Sun Wen, Director of Global Board of Directors, Beijing Yingke Law Firm, receiving the award at the eventHeadquartered in Beijing and established in 2001, Yingke Law Firm is a global legal service provider and a co-founder of the Global Coalition of Think Tank Networks for South-South Co-operation. Since 2022, Yingke has consistently held the top position in The Global 200 ranking of global law firms based on the number of lawyers, and its global legal service network has covered up to 199 cosmopolitan cities across 104 countries and territories. As the digital era approaches, Yingke is accelerating its “Digital Intelligence Law Firm” transformation and upgrading, with the aim of establishing a “Yingke Global One-Hour Legal Service Ecosystem” . The development strategy of the firm is also evolving from geographical business expansion to digital-intelligence transformation.“2025 marks the tenth anniversary of the IDC China Future Enterprise Awards. With the rapid advancement of artificial intelligence (AI) and its deep integration across industries, we are witnessing an increasing number of enterprises transforming into AI-driven firms as they enter the era of digital operation. These enterprises are customer-centric, open to experiment and constantly enhancing their products, services and user experiences,” said Mr. Wu Lianfeng, Vice President and Chief Analyst at IDC China. “Yingke Law Firm is a remarkable example of such organizations. From strategic vision to practical execution, Yingke actively adopts new technologies with an open and inclusive mindset, driving transformation within the legal sector. To streamline transformation, suppliers of innovative technologies and solutions like China Entercom play an indispensable role. As a trusted enabler of digital-intelligence transformation, China Entercom strives to offer clients with value-driven and reliable technologies and solutions. Moreover, as a successful example of international expansion, the company’s extensive experience and expertise in globalization provide valuable support for Chinese enterprises in their journey of going global.”Extending warm congratulations to Yingke Law Firm on its recognition as an Excellence Award winner at the 2025 IDC China Future Enterprise Awards, Mr. Henry Ko, General Manager at China Entercom, underlined the key to “Redefining Global Legal Services with Digital Intelligence” by integrating China Entercom’s ICT capabilities and Yingke’s expertise in digitalizing and globalizing legal services. He added that this cross-industry collaboration has reassured enterprises in their pursuit of globalization. “Our collaboration with Yingke began in 2021, when the firm embarked on its four strategic pillars — globalization, professionalization, digitalization and carbon neutrality — to optimize its worldwide operations and services,” said Mr. Ko. “We look forward to taking this collaboration to new heights, empowering enterprises to expand overseas and creating a new paradigm of legal and ICT innovations.”In today’s ever-changing economic and social landscape, every industry is confronted with new challenges, and these changes also raise the expectations for China Entercom. As an innovative ICT service enabler, the company is committed not only to staying ahead of technological advancement and strengthening its core capabilities, but also to gaining deeper insight into industry transformation and accumulating practical experience. Mr. Ko emphasized, “As AI is applied profoundly in various business scenarios, law firms and other enterprises are demanding higher standards in global network stability, data security and intelligence. As a result, more clients are partnering with China Entercom to explore efficient, flexible and future-ready models of digital and intelligent services.”Harnessing AI to Pioneer a New Legal Service ModelAs technology rapidly advances and the macro-environment evolves, the legal services industry finds itself in the midst of fierce competition, undergoing profound structural challenges in traditional legal services models. The first challenge stems from global economic integration, which has sharply increased demand for cross-border legal services. Law firms are now expected to demonstrate stronger global service capability, cross-regional collaboration, and the ability to deliver tailor-made services. Secondly, the rise of the digital economy has given birth to new legal issues, raising the standards of a firm’s knowledge base and learning agility. Finally, disruptive technologies such as AI are redefining the legal service eco-chain — from client acquisition and service scenarios to operational processes and service systems — prompting a comprehensive reconstruction and transformation.The “YingFaBao AI Legal Space Station” integrates Internet of Things (IoT), new media, videos and AI to deliver timely, efficient and one-stop self-service legal solutions, which marks a groundbreaking innovation in the legal services sector. In response to this new wave of transformation, China Entercom leverages over two decades of ICT practical experience and its strengths in integrated “Cloud, Network, Security” services to empower the digital and intelligent development of the legal services industry with AI-driven solutions. On one hand, it enhances the performance of critical digital infrastructure through global network optimization and intelligent security protection; on the other hand, this strong foundation supports law firms in all dimensions, such as digital management upgrades and global expansion of their services.Redefining Legal Services with Digital IntelligenceYingke Law Firm is developing a global legal data platform in the hope of creating a worldwide legal services platform through promoting data sharing and interconnection. According to Ms. Sun Wen, Director of Global Board of Directors at Beijing Yingke Law Firm, “As the wave of digitalization transforms the legal sector, Yingke has remained focused on advancing through technological innovation and professional excellence. On the journey to evolve our service models through the dual engines of ‘LegalTech + AI’, we are delighted to have China Entercom as a trusted partner. Its profound technical expertise and extensive experience in supporting enterprises going global provide invaluable insight for our strategic development and transformation in this new era.”China Entercom’s best practices in supporting enterprises “Going Global” and “Coming to China” have become a recognized benchmark. As a member of the CITIC Group, China Entercom upholds the service motto of “CITIC, Your Trusted Partner for Going Global and Coming to China”, and has long worked hand in hand with its parent companies, CITIC Telecom CPC and the Group, to extend service coverage to regions along the Belt and Road, the Middle East, BRICS nations and RCEP member countries. Its digital and intelligent solutions have already empowered numerous enterprises in overseas expansion. Today, China Entercom’s services span five continents and nearly 160 countries and regions, with global network resources connecting nearly 170 points of presence (POPs), 60 SD-WAN gateways, over 30 data centers, 20 cloud service centers, and three dedicated 24x7 Security Operations Centers (SOCs). Offering 99.99% network availability, the company ensures fast deployment and flexible scalability, thereby realizing faster, more stable, secure and compliant ICT services. Leveraging advanced AI technologies and services, namely its TrustCSI™ 3.0 cybersecurity solution suites and SIEM-MiiND intelligent SIEM platform, China Entercom delivers reliable, secure and high-efficiency data aggregation that provides the legal sector with smarter and more efficient digital intelligence.References:[1] Source: Yingke Law Firm official website.[2] Source: Yingke Law Firm official website.About International Data Corporation (IDC)IDC is the premier global market intelligence, data, and events provider for the information technology, telecommunications, and consumer technology markets. With more than 1,300 analysts worldwide, IDC offers global, regional, and local expertise on technology and industry opportunities and trends in over 110 countries. IDC's analysis and insight help IT professionals, business executives, and the investment community to make fact-based technology decisions and achieve their key business objectives. Establishing it’s China branch in 1982, IDC was the earliest global technology market research firm to enter the Chinese market. In China, IDC analysts focus on the local ICT market, producing research that covers areas including hardware, software, service, internet services, emerging technologies, and enterprise digital transformation. To learn more about IDC, please visit http://www.idc.com.About Yingke Law FirmYingke Law Firm is a global legal service provider established in 2001, headquartered in Beijing, China. Yingke is a Co-Founder of the Global Coalition of Think Tank Network for South-South Cooperation. Since 2022, we have consistently held the top position in The Global 200 ranking of global law firms based on the number of lawyers. Yingke Law Firm is committed to improving the "Yingke Global One-Hour Legal Service Ecosystem", and its headquarters adopt the mode of "direct investment and direct management" for up to 126 offices across mainland China and one joint law firm in the Guangdong-Hong Kong-Macao region. So far, Yingke's global legal service network has covered up to 199 cosmopolitan cities across 104 countries and territories. For more information, please visit https://www.yingkelawyer.com/index.html.About China EntercomChina Enterprise ICT Solutions Limited (“China Entercom” or “CEC”), a subsidiary of the CITIC Group. With solid global knowledge, diversified industrial experience, successful cases and top-notch expertise, as well as incorporating extensive ICT resource coverage, global-local capabilities and world-class solutions, China Entercom stands as the trusted partner for comprehensive solutions, addressing customers’ specific ICT requirements and fostering their development along the “Belt and Road” and around the globe. For more information, please visit https://www.china-entercom.com/En/.About CITIC Telecom CPCWe are CITIC Telecom International CPC Limited (“CITIC Telecom CPC”), a wholly-owned subsidiary of CITIC Telecom International Holdings Limited (SEHK: 1883), serving multinational enterprises the world over by addressing their specific ICT requirements with highly scalable tailored solutions built upon our flagship technology suites, comprising TrueCONNECT™ private network solutions, TrustCSI™ information security solutions, DataHOUSE™ cloud data center solutions, and SmartCLOUD™ cloud computing solutions.With the motto “Innovation Never Stops,” we leverage innovative technologies to boost technology empowerment (+AI). Embracing AI, AR, Big Data, IoT, and other cutting-edge emerging technologies we aim to unlock technical potential. By integrating deep learning and intelligent data analysis technologies, we transform these technologies into data empowerment (AI+) generative applications, reshaping the Intelligence Operation Journey of enterprises.With our Global-Local capabilities, we are committed to providing our customers with one-stop-shop ICT solutions with superior quality. Having a worldwide footprint across nearly 160 countries and regions, including Asia, Europe and America, Africa, the Middle East, and Central Asia, our global network resources connect nearly 170 points of presence (POPs), 60+ SD-WAN gateways, 20 Cloud service centers, 30+ data centers, and three dedicated 24x7 Security Operations Centers (SOCs). We are certified with a series of international certifications, including SD-WAN Ready, ISO 9001, 14001, 20000, 27001, and 27017, to ensure our services compliance with international standards and resources for enterprises. We offer local professional services, superior delivery capabilities as well as exceptional customer experience and best practices through our global presence and extensive industry know-how, becoming a leading integrated intelligent ICT service provider to enterprise customers.For more information, please visit www.citictel-cpc.com.Media Contacts:Catherine YuenCITIC Telecom CPC(852) 2170 7536Email: catherine.yuen@citictel-cpc.com Copyright 2025 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com
More